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Abstract 
Background: Lung cancer is the most commonly diagnosed cancer and the leading cause 
of cancer-related deaths in Canada. Over the last decade, significant advancements in 
treatments for non-small-cell lung cancer (NSCLC) have been made. Development of 
novel therapies such as tyrosine kinase inhibitors (TKIs) and immunotherapies (i.e., 
immune checkpoint inhibitors) have offered a new paradigm for the treatment of NSCLC. 
While several randomized controlled trials demonstrated the efficacy of TKIs and 
immunotherapies, the comparative effectiveness and cost-effectiveness of these therapies 
in real-world setting remains unclear. 
Objectives: The overall aim of this dissertation was to investigate the comparative 
clinical and cost-effectiveness of first- (i.e., EGFR-TKIs) and second-line therapies (i.e., 
immunotherapies) for the treatment of NSCLC in Ontario, Canada. 
Methods: This thesis is presented as three individual studies included in Chapters 3 to 5. 
Study 1 aimed to investigate the effectiveness of immunotherapies for non-small-cell 
lung cancer in a real-world clinical setting, as this currently remains uncertain. 
Systematic searches of PubMed, EMBASE and Web of Science were performed; a 
narrative synthesis was conducted on all included studies, with the synthesis being 
stratified by variables including age, sex, histology, prior lines of treatment, brain 
metastasis, and ECOG-PS. Separate random-effects models were used to estimate pooled 
median overall survival (OS) and progression-free survival (PFS) estimates. Study 2 
aimed to investigate the factors associated with treatment selection and OS for first-line 
EGFR-TKI therapy among patients with non-small-cell lung cancer. A retrospective 
cohort study of linked administrative health databases in Ontario, Canada was conducted. 
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To explore the factors associated with treatment selection, we conducted two separate 
logistic regression analyses comparing afatinib to gefitinib and erlotinib to gefitinib. 
Discrimination of the models was assessed with the area under the receiver operating 
characteristic curve. Calibration of the models was evaluated using the Hosmer 
Lemeshow goodness-of-fit tests. OS was assessed using the Kaplan-Meier method on the 
overall population and various patient subgroups. The OS was calculated from the date of 
diagnosis of NSCLC to death (for any reason) or the last day of patient follow-up 
(censored). Comparisons between groups were performed using the log rank test. 
Multivariable Cox proportional hazards models were used to determine adjusted hazard 
ratios and to evaluate the predictive factors for survival. In Study 3, a net benefit 
regression approach accounting for baseline covariates and propensity scores was used to 
estimate incremental net benefits and incremental cost-effectiveness ratios. Inverse 
probability of censoring weights was applied for differential censoring. Outcome 
measures were calculated over a 68-month period and were discounted with an annual 
rate of 1.5%. Sensitivity analyses were conducted to assess and characterize the 
uncertainties. 
Results: Results from Study 1 provided insights on the effectiveness of 
immunotherapies, particularly nivolumab, in real-world clinical practice. 36 studies of 
nivolumab were included for narrative synthesis and 11 of these studies were included for 
meta-analysis. Age, sex, histology and prior lines of treatment did not affect survival 
outcomes, while Eastern Cooperative Oncology Group Performance Status and brain 
metastasis were inversely associated with survival. In the meta-analysis, nivolumab was 
associated with 9.6 months (95% CI: 8.4–10.9) of overall survival and 2.6 months (95% 
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CI: 1.6–3.6) of progression-free survival. Empirical evidence suggested the real-world 
effectiveness of nivolumab was consistent with those observed in the clinical trials. 
Results from Study 2 identified the patient characteristics influencing the treatment 
selection and overall survival associated with EGFR-TKI therapy. From 01 January 2010 
through 31 August 2019, a total of 1,078 patients received an EGFR-TKI as first-line 
therapy. Of these, 1,011 patients met the eligibility criteria and were included in the 
study. Treatment selection and OS associated with these treatments were affected by age, 
sex, geographical residency, comorbidities, and different sites of metastasis. Though 
recent approval of osimertinib offers a potential new standard of care in the first-line 
setting, earlier generation TKIs remain pillars in the treatment of NSCLC therapeutic 
armamentarium. The findings of this study may contribute to optimizing the treatment 
sequencing of EGFR-TKIs to maximize clinical benefits. Results from Study 3 
investigated the comparative cost-effectiveness of EGFR-TKIs in Ontario, Canada. From 
01 January 2014 and 31 August 2019, a total of 547 patients met the eligibility criteria 
and were included in the study. 20.1%, 23.6%, and 56.3% received afatinib, erlotinib, and 
gefitinib, respectively. Erlotinib was dominated by afatinib and gefitinib. Compared to 
gefitinib, afatinib was associated with higher effectiveness (adjusted incremental quality-
adjusted life-year: 0.21), higher total costs (adjusted incremental costs: $9745), and an 
incremental cost-effectiveness ratio of $46,506 per quality-adjusted life-year 
gained. Results from the sensitivity analyses indicated the findings of the base-case 
analysis were robust. Our findings suggest afatinib was the most cost-effective option 
among the three EGFR-TKIs. 
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Conclusion: This dissertation investigated real-world clinical and cost-effectiveness of 
EGFR-TKIs and immunotherapies (nivolumab) for the first- and second-line treatments 
for NSCLC, and identified patient factors influencing treatment selection and overall 
survival associated with EGFR-TKI treatment. The findings presented throughout this 
thesis may contribute to the body of knowledge in regard to optimization of treatment 
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Chapter 1: Introduction 
Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer-related deaths in 
Canada, with an estimated 29,800 new cases and 21,200 deaths in 2020 (Canadian Cancer Society, 
2021).  Non-small cell lung cancer (NSCLC) is the most common histological subtype, representing over 
80% of all lung cancer cases (Canadian Cancer Society's Advisory Committee on Cancer Statistics, 
2018; Cancer Care Ontario, 2018). The five-year survival rate in Canada for lung cancer is 
approximately 19%; despite the improved survival rate in recent years, the level of survival 
advancements seen in other forms of cancer (e.g., breast [88%], prostate [95%]), has yet to be seen in 
lung cancer (Canadian Cancer Society's Advisory Committee on Cancer Statistics, 2018; 
Canadian Cancer Society, 2020) 
Increasing understanding of biology of cancer has led to recent advancements in personalized therapy. 
These advancements allow us to stratify patients by their histological and molecular subtypes to guide 
selection of therapeutic strategies in efforts to maximize clinical benefits and minimize treatment-related 
adverse events (AEs) (Korpanty et al., 2014; Naidoo, 2014). Selected patients harboring oncogenic 
drivers such as epidermal growth factor receptor (EGFR) are eligible to receive tyrosine kinase inhibitors 
(TKIs) targeted to these genetic tumor aberrations, which improve survival and prolong disease control. 
However, patients often acquire resistance and treatment-related adverse events with TKIs. The long-
term prognosis remains poor and all patients eventually progress through the disease (Wu & Shih, 2018). 
In addition to TKIs, immunotherapy (i.e., immune checkpoint inhibitors) offer a new paradigm for the 
treatment of NSCLC, which targets the programmed cell death-1 (PD-1) and programmed cell death 
ligand 1 (PD-L1) pathway. Evasion and manipulation of the immune system is a primary feature of 
cancers and enables tumor growth and metastasis (Beatty & Gladney, 2015; Muenst et al., 2016; Vinay 
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et al., 2015). Understanding the tumor evasion mechanism via the PD-1/PD-L1 signaling pathway 
contributed to the development of immune modulating therapies, which amplify one’s own immune 
system to recognize and kill cancer cells.  
Being able to selectively identify which patients would benefit the most from personalized therapies and 
immunotherapies would be of major clinical advancement in lung cancer management. With new 
generation of therapies emerging, investigation of the clinical benefits of these therapies, along with their 
cost-effectiveness is important to help select the most optimal treatment sequences for patients with 
NSCLC and optimize health care resource allocations. Thus, the aim of this thesis was to investigate the 
clinical and cost-effectiveness of first line (i.e., EGFR-TKIs) and second line (i.e., immune checkpoint 
inhibitors) treatments for EGFR mutation-positive NSCLC in Ontario, Canada. 
1.1. Dissertation Overview 
This dissertation consists of three linked manuscripts with an expanded introduction and discussion. The 
dissertation begins with the introduction to background information and a review of the literature in 
Chapter 2. The literature review focuses on the disease information, epidemiology, treatment protocols, 
economic burden, and cost-effectiveness of interventions associated with NSCLC. Chapters 3-5 have 
been written for publication and presents the three primary studies conducted for the dissertation. 
Chapter 3 was published in Future Oncology; Chapter 4 has been published in the Journal of 
Comparative Effectiveness and Research and Chapter 5 has been published in PharmacoEconomics. 
Chapter 6 connects all three primary studies and discusses the implications of this dissertation and 




1.2.  Research Rationale 
The first study investigated the effectiveness and safety of approved immunotherapies for the treatment 
of NSCLC in clinical practice through a systematic review of the literature. Among non-oncogene 
addicted lung cancer patients, immune checkpoint inhibitors have demonstrated superior efficacy over 
standard chemotherapy (e.g., docetaxel) with regards to overall survival (OS) and progression-free 
survival (PFS). However, evidence to date suggest the benefits of immune checkpoint inhibitors lack 
clinical activity in EGFR mutant lung cancer patients. Several observational studies reporting on the 
effectiveness and safety of immunotherapies for NSCLC in routine clinical practice have been published 
to date. We sought to collect and synthesize all empirical evidence to further understand the 
effectiveness of immunotherapies in the real-world and determine whether the effectiveness was 
comparable to what was observed in clinical trials for lung cancer patients overall (i.e, non-oncogene 
addicted lung cancer patients), and to synthesize results by mutation type (e.g., KRAS, EGFR, ALK, 
HER2), if available. 
The second study investigated the patient factors that influenced treatment selection of first-line EGFR-
TKIs and overall survival among EGFR mutation-positive NSCLC patients in routine clinical practice. 
Evidence-based clinical practice guidelines have been developed for prescribing these therapies to 
minimize adverse effects (AEs) and maximize clinical benefits. With new generations of EGFR-TKIs 
emerging and a number of treatment options becoming available, it is important to identify a proper 
agent for each patient in clinical practice to balance the risks and benefits. Leveraging the population-
level data from ICES, we sought to investigate whether certain demographic or clinical factors 
systematically influence prescribing decisions and survival in Ontario, Canada. 
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The last study examined the comparative cost-effectiveness of first-line EGFR-TKIs (i.e., afatinib, 
erlotinib, and gefitinib) for the treatment of EGFR mutation-positive NSCLC. Although multiple 
economic evaluations have been conducted to date, the majority were model-based analyses with 
information derived from multiple trials to infer effectiveness using indirect treatment comparisons. The 
use of model analyses is associated with many limitations such as incorporation of model assumptions 
(e.g., Markovian assumption), restrictive inclusion and exclusion criteria, limited lengths of follow-up, 
extrapolation of observed survival data, and limited information on treatment-related healthcare costs. 
Hence, we sought to conduct a cost-effectiveness analysis using population-based, person-level claims 
data, which permit direct comparison of effectiveness and costs associated with TKIs for the treatment of 
EGFR mutation-positive NSCLC. Specific objectives were as follows: 
Study 1:  Real-world effectiveness of nivolumab in patients with non-small-cell lung cancer: a 
systematic review and meta-analysis 
Objective: To investigate the effectiveness and safety of immune checkpoint inhibitors for 
the treatment of NSCLC in real-world settings. 
Study 2:  Factors affecting treatment selection and overall survival for first-line EGFR-TKI 
therapy in non-small-cell lung cancer 
Objective: To examine the demographic and clinical factors influencing treatment selection 
and overall survival associated with first-line EGFR-TKIs for the treatment of NSCLC in 
Ontario, Canada. 
Study 3:  Cost-effectiveness analysis of afatinib, erlotinib, and gefitinib as first-line treatment for 
EGFR mutation-positive non-small-cell lung cancer in Ontario, Canada 
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Objective: To investigate the comparative cost-effectiveness of first-line EGFR-TKIs for the 
treatment of patients with advanced EGFR mutant NSCLC in Ontario, Canada. 
Chapter 2: Literature Review 
2.1. Categorization of Lung Cancer 
2.1.1. Histologic Subtype 
Lung cancer is a form of cancer whereby malignant carcinoma cells develop in the lining of the air 
passageway of the lungs (American Cancer Society, 2016a, 2016b) . Lung cancer can be broadly 
classified as NSCLC and small-cell lung cancer (SCLC). NSCLC accounts for 80%-85% of all lung 
cancer cases, while SCLC accounts for the remaining 10%-15% (American Cancer Society, 2016a, 
2016b; Lung Cancer Alliance, 2018) . 
NSCLC is the most common type of lung cancer and can be divided into three subtypes – 
adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Adenocarcinoma is a slow growing 
form of lung cancer usually found in the outer region of the lung. Adenocarcinoma is the most common 
form of NSCLC, accounting for 40% to 50% of all lung cancer cases (American Cancer Society, 2016a). 
Adenocarcinoma is more prevalent among smokers though it is also the most common form of lung 
cancer in non-smokers as well (American Cancer Society, 2016a; National Cancer Institute, 2018). 
Squamous cell carcinoma most frequently develops in the center of the chest area in the bronchi and is 
highly correlated with history of tobacco consumption. Squamous cell carcinoma accounts for 25% to 
30% of all lung cancer cases (American Cancer Society, 2016a; National Cancer Institute, 2018). Large 
cell carcinoma is the least common type of NSCLC, accounting for 10% to 15% of all lung cancer cases 
(American Cancer Society, 2016a). Large cell carcinoma can occur anywhere in the lung and is able to 
grow and metastasize at a rapid rate. Staging of NSCLC is done by using the Tumor, Node, Metastasis 
(TNM) Classification of Malignant Tumours staging system (Table 1, Table 2). 
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Table 1. TNM Descriptor 
T (Primary Tumor) 
T0 No evidence of tumor 
Tis Carcinoma in situ (squamous or carcinoma) 
T1 Tumor ≤ 3cm 
T1mi Minimally invasive carcinoma 
T1a Tumor ≤ 1cm 
T1b Tumor > 1 but ≤ 2cm 
T1c Tumor > 2 but ≤ 3cm 
T2 
Tumor > 3 but ≤ 5cm or involvement of main bronchus (not carina), visceral pleura, 
atelectasis to hilum 
T2a Tumor > 3 but ≤ 4cm 
T2b Tumor > 4 but ≤ 5cm 
T3 
Tumor >5 but ≤ 7cm in greatest dimension or tumor of any size invading chest wall, 
pericardium, phrenic nerve or separate tumor nodules in the same lobe. 
T4 
Tumor > 7cm in greatest dimension or any tumor invading mediastinum, diaphragm, 
heart, great vessels, recurrent laryngeal nerve, carina, trachea, esophagus, spine or 
tumor nodules in a different ipsilateral lobe 
N (Regional Lymph Node) 
N0 No regional node metastasis 
N1 Metastasis in ipsilateral peribronchial or hilar nodes and intrapulmonary nodes 
N2 Metastasis in ipsilateral mediastinal or subcarinal nodes 
N3 
Metastasis in contralateral mediastinal, hilar, or ipsilateral/contralateral 
scalene/supraclavicular nodes 
M (Distant Metastasis) 
M0 No distant metastasis 
M1a Tumor in contralateral lung or pleural/pericardial nodule or malignant pleural 
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T (Primary Tumor) 
M1b Single extrathoracic metastasis 
M1c Multiple extrathoracic metastases in one or more organs 
Source: AJCC Cancer Staging Manual 8
th 
Edition, 2017 
Table 2 TNM Staging for NSCLC 
T/M Subcategory N0 N1 N2 N3 
T1 
T1a IA1 IIB IIIA IIIB 
T1b IA2 IIB IIIA IIIB 
T1c IA3 IIB IIIA IIIB 
T2 
T2a IB IIB IIIA IIIB 
T2b IIA IIB IIIA IIIB 
T3 T3 IIB IIIA IIIB IIIC 
T4 T4 IIIA IIIA IIIB IIIC 
M1 
M1a IVA IVA IVA IVA 
M1b IVA IVA IVA IVA 
M1c IVB IVB IVB IVB 
Source: AJCC Cancer Staging Manual 8
th 
Edition, 2017 
The stage of cancer describes how much cancer is in the body and helps to determine the magnitude of 
cancer and the course of treatment that is necessary. Information on staging is also used for implications 
in survival statistics (e.g., five-year survival rate), as well as a prognostic factor for health outcomes. The 
earliest stage of NSCLC is stage 0 (i.e., carcinoma in situ); other stages range from I through IV, with 
stage IV denoting the highest stage indicating increased metastasis. In terms of the TNM staging, higher 
numbers associated with each letter indicates a higher stage. Most lung cancer patients are diagnosed at 
stage IV (Figure 1). 
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Figure 1 Percentage distribution of lung cancer cases by stage at diagnosis 
Source: Canadian Cancer Statistics: A 2018 Special Report 
2.1.2. Molecular subtype 
NSCLC can be further defined at the molecular level. Research into the genetics of lung cancer has led 
to the discovery of several gene mutations, amplifications, and rearrangements in multiple oncogenes 
such as AKT1, ALK, BRAF, EGFR, HER2, KRAS, MEK1, MET, NRAS, PIK3CA, RET, and ROS1 (El-
Telbany & Ma, 2012; Zhu et al., 2017). Cancer develop as a result of the accumulation of these genomic 
alterations, which results in cell growth, proliferation, resistance to apoptosis, and eventually 
tumorigenesis – such mutations are called “driver mutations” (Pakkala & Ramalingam, 2018; Zhu et al., 
2017). Mutations are found in all histological types of lung cancer and up to 50% of NSCLC patients 
harbor a driver mutation (Pakkala & Ramalingam, 2018). The frequency of driver mutations is presented 
in Figure 2. The incidence and prevalence of driver mutations in non-small-cell lung cancer varies by 
countries and ethnicities (Dearden et al, 2013; Midha et al, 2015). 
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Figure 2 Frequency of driver mutations in NSCLC 
Source: Pakkala & Ramalingam, 2018 
2.2. Epidemiology 
2.2.1. Incidence 
Lung cancer is the leading cause of cancer-related mortality in the province of Ontario, Canada and 
worldwide. Approximately 29,800 new cases of lung cancer were diagnosed in Canada in 2020, the 
equivalent of 81 lung cancers diagnosed per day (Canadian Cancer Society, 2020). Lung cancer is the 
second most common cancer diagnosis for each sex, behind prostate cancer for men and breast cancer 
for women (Canadian Cancer Society, 2020). In 2020, approximately 15,000 men were diagnosed with 
lung cancer and 11,000 died from it, while 14,800 women were diagnosed and 10,200 died 
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(Canadian Cancer Society, 2020). The incidence rate is higher for males than females, with age-
standardized incidence rates of 76.5 and 65.3 per 100,000 persons, respectively 
(Canadian Cancer Society's Advisory Committee on Cancer Statistics, 2018). 
Recent trends suggest incidence rates have declined for both sexes. Incidence rates for men in Canada 
have declined since 1983 (Canadian Cancer Society's Advisory Committee on Cancer Statistics, 2017), 
in conjunction with declines in tobacco consumption following a rise in awareness of the risks of tobacco 
smoking and the implementation of governmental tobacco control measures. The incidence rates have 
decreased more for men than women due to differences in smoking uptake and cessation. Among 
females, incidence rates rose until 2006 and levelled off thereafter 
(Canadian Cancer Society's Advisory Committee on Cancer Statistics, 2018). 
2.2.2. Mortality 
On average, 58 Canadians die from lung cancer every day. Mortality rate is higher for males than 
females, with age-standardized mortality rates (ASMR) of 59.4 and 45.3 per 100,000 persons, 
respectively (Canadian Cancer Society's Advisory Committee on Cancer Statistics, 2018). Among males, 
the age-standardized mortality rate began to level off in the late 1980s and saw a gradual decline from 
1989 onwards (Canadian Cancer Society's Advisory Committee on Cancer Statistics, 2017). 
Among females, the ASMR continued to increase until 2000 and gradually decreased moving forward 
(Canadian Cancer Society's Advisory Committee on Cancer Statistics, 2017). Decreases in mortality 
rates for both sexes are largely due to reduced tobacco use, which began in the late 1950s for men and 
mid-1970s for women (Canadian Cancer Society's Advisory Committee on Cancer Statistics, 2017). 
2.2.3. Survival 
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The five-year survival rate in Canada for lung cancer is 19% (Canadian Cancer Society, 2020). Although 
recent trends suggest the five-year survival rate has improved gradually over the years (Figure 3), it 
remains relatively low compared to other major forms of cancers such as prostate (95%), breast (88%), 
and colorectal cancer (64%). The low survival rate may be explained in part due to patients’ advanced 
clinical stage at the time of initial diagnosis, when the tumor has grown large and metastasized to other 
parts of the body. 
Figure 3 Five-year survival rate for lung cancer in Canada in 1995-1999 and 2005-2009 
 
Source: Lung Cancer Canada: 2015 Faces of Lung Cancer Report 
2.3. Risk Factors, Signs, and Symptoms 
Numerous factors have been identified as risk factors for developing lung cancer, including but not 
limited to tobacco consumption, age, sex, family history of lung cancer, and exposure to environmental 
factors such as radon, asbestos, and air pollution (Alberg et al., 2007; Anderson et al., 2003; 
Canadian Cancer Society's Advisory Committee on Cancer Statistics, 2018; Gray et al., 2009; Lissowska 
et al., 2010; Straif et al., 2009). 
Tobacco consumption has been identified as the leading cause of lung cancer development. The risk of 
developing lung cancer was estimated to be 20-40 times higher for lifelong smokers than non-smokers 
(Ozlü & Bülbül, 2005). It is estimated that the risk of developing lung cancer declines by 39% five years 
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after smoking cessation, although it will not return to that of never-smokers (Tindle et al., 2018). 
Exposure to second-hand smoke was identified as the next most common contributor to development of 
lung cancer. Non-smokers who have lived with smokers and were exposed to second-hand smoke had 
20%-30% increased risk in developing lung cancer (U.S. Department of Health and Human Services, 
2014). Exposure to radon-gas was the leading non-tobacco related cause of lung cancer; approximately 
10% of all lung cancer incidence in Canada may be attributed to indoor radon exposure (Chen et al., 
2012). 
Lung cancer tends to be asymptomatic in its early stages. It has a long latency period where cancer cells 
grow for many years without being noticed; consequently, patients are often diagnosed in the advanced 
stages of disease, after the cancer has metastasized to other parts of the body. At its early stages, 
symptoms conform to other common diseases such as seasonal flu or common cold. Symptoms may 
include persistent cough, chest pains, weight loss, shortness of breath, fatigue, and hoarseness 
(American Cancer Society, 2016a, 2016b; National Cancer Institute, 2018). As cancer worsens and 
metastasize to the brain, liver, bone, and lymph nodes, symptoms such as severe coughs, swelling in the 
face or neck, difficulty in swallowing, pain in the bones, numbness in limbs, and jaundice become 
apparent enough to seek medical attention (American Cancer Society, 2016a, 2016b). 
2.4. Screening & Testing 
The Canadian Task Force on Preventive Health Care has recommended screening with low-dose 
computed tomography (LDCT) every year for three consecutive years for high-risk individuals 
(Canadian Task Force on Preventive Health Care, 2016). High-risk individuals are defined as adults 
between the age of 55 and 74 years with history of smoking within the past 15 years and at least a 30-
pack year smoking history (Canadian Task Force on Preventive Health Care, 2016). The underlying 
principle of screening is to detect a disease in its early stages to enable the use of less invasive types of 
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treatments and decrease overall mortality. Since lung cancer is asymptomatic in its early stages, 
screening offers the possibility of identifying lung cancer patients that would otherwise go undetected. 
Detection of tumors at earlier stages can lead to improved prognosis and increased likelihood of 
treatment success. The five-year survival rate for stage IA NSCLC is 77-92% in Canada compared to 0-
10% for stage IV NSCLC (Canadian Cancer Society's Advisory Committee on Cancer Statistics, 2017). 
Approximately 1.4 million Canadians have been classified as high-risk and were eligible for LDCT 
screening in 2018 (Evans et al., 2016). 
Several tests are available and conducted to confirm the diagnosis of lung cancer. Tests may include x-
rays, magnetic resonance imaging (MRI), positron emission tomography (PET) scans, and computed 
tomography (CT) scans to reveal an abnormal mass or nodule on the lungs (National Cancer Institute, 
2018). CT scans are used to reveal small lesions in the lungs that may otherwise be undetected in x-rays, 
while MRIs are used to locate the tumor and/or metastases and measure the tumor’s size. 
(American Cancer Society, 2016a, 2016b). Biopsy and pathology review may be performed to establish 
tissue diagnosis, which includes the use of immunohistochemistry (Canadian Cancer Society, 2021). In 
addition, blood tests such as complete blood count and platelets or metabolic profile are commonly 
conducted (Canadian Cancer Society, 2021). It is recommended that the first staging tests be the least 
invasive method with the highest diagnostic yield rate, which may include bronchoscopy with 
transbronchial needle aspiration, endobronchial ultrasound-guided needle aspiration, endoscopic 
ultrasound-guided needle aspiration, transthoracic needle aspiration, or mediastinoscopy (Canadian 
Cancer Society, 2021; Darling et al., 2018).Results from these tests are used to reveal specific 




Treatment options can vary depending on one’s overall health, along with the type and stage of the 
cancer. Treatment of lung cancer includes surgery (wedge resection, segmental resection, lobectomy, 
pneumonectomy), systemic therapy, radiation therapy, chemotherapy, radiosurgery, and supportive care 
(National Cancer Institute, 2018). There is no cure for patients with stage IIIB/IV NSCLC; therefore, 
palliative treatment is commonly used for advanced NSCLC to effectively manage symptoms. The 
below section outlines treatments by line of therapy for EGFR mutation-positive NSCLC. 
2.5.1. First-line treatment – EGFR mutation-positive 
For patients with sensitizing EGFR mutations, one of osimertinib (Tagrisso®, AstraZeneca), afatinib 
(Giotrif®, Boehringer Ingelheim), erlotinib (Tarceva®, Roche), or gefitinib (Iressa®, AstraZeneca) is 
recommended (Melosky et al., 2020). Gefitinib was the first EGFR-TKI to be approved by Health 
Canada in December 2003 as a third-line treatment for NSCLC. In December 2009, Health Canada 
approved expanded indication for gefitinib for use in the first-line setting for patients with EGFR 
activating mutations in tumor. Erlotinib was first approved in July 2005 and indicated as second- or 
third-line treatment for NSCLC (irrespective of the presence of EGFR mutations), following failure of 
first- or second- line chemotherapy. In August 2012, Health Canada approved an additional indication 
for erlotinib as a first-line therapy for patients with activating mutations in EGFR with NSCLC. Afatinib 
was approved by Health Canada in 2013 as a first-line monotherapy for the treatment of metastatic 
adenocarcinoma of the lung with activating EGFR mutations. Osimertinib was the first third-generation 
EGFR-TKI to receive Health Canada approval on July 2018 for treatment of locally advanced or 
metastatic NSCLC patients whose tumors have EGFR exon 19 deletions or exon 21 substitution 
mutations. The four TKIs are currently funded under the Exceptional Access Program in Ontario. 
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All four agents are orally administered and work to inhibit the activity of the EGFR tyrosine kinase, an 
enzyme that regulates the EGFR signaling pathway. All agents showed statistically significant 
improvements in PFS and overall response rate (ORR), along with minor improvements in OS compared 
to standard chemotherapy regimens in the first-line setting (Maemondo et al., 2010; Rosell et al., 2012; 
Yang et al., 2017; Zhou et al., 2011). Osimertinib is currently the preferred first-line treatment for 
patients with advanced NSCLC whose tumors harbor common EGFR mutations (exon19del and L858R); 
the phase III FLAURA trial demonstrated significant improvement in OS with osimertinib compared to 
first-generation EGFR-TKIs (Soria et al., 2018; Ramalingam et al., 2020). However, the upfront use of 
osimertinib in the first-line setting is associated with concerns about the restricted treatments options for 
later lines of therapy. 
2.5.2. Second-line treatment – EGFR mutation-positive 
For patients harboring EGFR mutations who did not respond to first-line EGFR TKIs, combination 
platinum-based cytotoxic chemotherapy is recommended (Ellis, 2016; Melosky et al., 2020). In addition, 
osimertinib is recommended for patients with acquired T790M mutation (Ellis, 2016; Melosky et al., 
2020). For patients with an exon 20 insertion who progressed from first-line platinum-based cytotoxic 
chemotherapy, docetaxel is recommended (Melosky et al., 2020). 
2.5.3. Third-line treatment – EGFR mutation-positive 
For patients who progressed from platinum-based chemotherapy in the second-line setting, docetaxel is 
recommended (Melosky et al., 2020). For patients who acquired T790M mutation and received 




2.6. Economic Burden of Lung Cancer 
Lung cancer is associated with substantial economic burden for the health care system in Canada. In 
Ontario, the total direct cost for all NSCLC patients was $1.9 billion from 2010-2015, while the mean 
cost per patient was $76,816 (Seung et al., 2019). By 2040, direct costs associated with lung cancer 
could exceed $7.9 billion per year in Ontario (Smetanin et al., 2011). 
Similar trends were observed in the US and Europe. In 2009, the total cost of cancer in the EU was €126 
billion, of which lung cancer accounted for €18.8 billion or 15% of the overall cancer costs (Luengo-
Fernandez et al., 2013). In 2015, the total cost of cancer in the US was $183 billion and the overall costs 
were projected to increase by 34% to $246 billion by 2030 (Mariotto et al., 2020). The economic burden 
of lung cancer is projected to rise globally in the coming years mainly due to the aging population and 
increases in the costs of associated treatments. 
2.7. Cost-Effectiveness 
Economic evaluation aims to quantify the comparative costs and benefits of adopting new intervention 
for health conditions versus continuing to use existing treatments for the same conditions (Drummond, 
2015; Jakubiak-Lasocka & Jakubczyk, 2014). It provides a framework to systematically assess the 
combinational value of clinical evidence, health care costs, and other effects (e.g. quality of life) 
(Drummond, 2015). The main purpose of economic evaluations is to help policymakers optimize 
resource allocation decisions in health care. 
One of the most widely used forms of economic evaluation is cost-effectiveness analysis (CEA). CEA 
allows us to examine the costs of alternative approaches to achieving a specific health outcome 
(Drummond, 2015; Leung, 2016). CEAs measure health benefits/outcomes in natural units (e.g. number 
of falls prevented), which are usually clinically relevant. 
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The main output of CEA is the incremental cost-effectiveness ratio (ICER), which is a summary measure 
representing the economic value of an intervention. The ratio statistic is calculated by dividing the 
difference in costs between the competing interventions (numerator) over the difference in effectiveness 
(denominator). The costs of the existing treatment are subtracted from the costs of the new intervention 
in the numerator, and the same is done with the measure of effectiveness in the denominator such that 
the ICER shows the cost of obtaining one additional unit of effect if one switches from the existing 
therapy to a new therapy (Cohen & Reynolds, 2008; Drummond, 2015; Hoch & Dewa, 2008). Once 
ICER is calculated, it is compared with a predefined threshold value, also known as willingness-to-pay 
threshold (WTP), to determine whether the intervention is cost-effective. Five possible outcomes can be 
inferred from the ICER. The intervention can be 1) more expensive and more effective, 2) more 
expensive and less effective (dominated), 3) less expensive and more effective (dominates), 4) less 
expensive and less effective, and 5) neutral (costs and effects are the same). 
2.8. Cost-effectiveness of EGFR-TKIs 
Numerous economic evaluations have been conducted to date, which assessed the cost-effectiveness of 
EGFR-TKIs across all settings. However, majority of the existing economic evaluations have either 
compared one EGFR-TKI to best supportive care (e.g., chemotherapy) or inferred efficacy/effectiveness 
estimates from indirect treatment comparisons using information derived from multiple trials. Of the 
existing literature, three studies compared an EGFR-TKI to best supportive care (Khan et al., 2015; Tan 
et al., 2018; Wen et al., 2018). Two studies compared afatinib and gefitinib (Chouaid et al., 2017; Wang 
et al., 2019), while one study compared erlotinib and gefitinib (Lee et al., 2014), and the remaining 
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studies compared multiple EGFR-TKIs simultaneously (Arrieta et al., 2020; Gu et al., 2019; Holleman et 
al., 2020; Kimura et al., 2018; Ting et al., 2015; Yang et al., 2020).  
Apart from studies which investigated the cost-effectiveness of EGFR-TKIs using observational data 
(Arrieta et al., 2020; Yang et al., 2020) or the LUX-Lung 7 trial (Chouaid et al., 2017; Wang et al., 2019) 
where head-to-head data were available, other studies have sourced information from multiple trials and 
indirectly compared the efficacy/effectiveness estimates to calculate the ICER. Studies have reported 
differing results with varying ranges of ICERs and no clear patterns. Therefore, there is no concrete 
evidence to suggest which EGFR-TKI is the most cost-effective option. A summary of the study findings 
is reported in Table 3. 
 
19 





Author Year Country Perspective Therapy Data Sources ICER
Arrieta et al. 2020 Mexico Payer Afatinib, Erlotinib, Gefitinib
Medical records at Instituto Nacional de 
Cancerologia (INCan)
Erlotinib dominated by afatinib and gefitinib
PFS: Afatinib vs. Gefitinib: $145,625 MXN/LY
OS: Afatinib vs. Gefitinib: $18,640 MXN/LY
Chouaid et al. 2017 France Payer Afatinib vs. Gefitinib Lux-Lung 7
ITT: €45,211/QALY
Exon Leu858Arg: €52,518/QALY
Exon 19 Del: €38,970/QALY
Gu et al. 2019 China Payer Afatinib vs. Erlotinib, Gefitinib, PC
Lux-Lung 3, Lux-Lung 6, Lux-Lung 7, First-
SIGNAL, OPTIMAL, EURTAC, ENSURE, IPASS, 
NEJ002, WJTOG3405
Afatinib vs. PC: $20,758/QALY
Afatinib vs. Gefitinib: $17,693/QALY
Afatinib vs. Erlotinib: $16,197/QALY 
Holleman et al. 2020 The Netherlands Payer
Afatinib, Erlotinib, Gefitinib, 
Osimertinib
NEJ002, WJTOG3405, IPASS, First-SIGNAL, 
OPTIMAL, EURTAC, ENSURE, Lux-Lung 3, Lux-
Lung 6, Lux-Lung 7, CTRONG0901, FLAURA
Gefitinib dominated by Erlotinib
Afatinib vs. Erlotinib: €27,058/LY and 
€41,504/QALY
Osimertinib vs. Afatinib: €91,726/LY and 
€128,343/QALY
Khan et al. 2015 UK Payer Erlotinib vs. BSC TOPICAL Erlotinib vs. BSC: £202,571/QALY
Kimura et al. 2018 Japan Payer Gefitinib vs. Afatinib, Erlotinib RCTs - not specified
Gefitinib vs. Afatinib: 122,070/MST (JPY)
Gefitinib vs. Erlotinib: 69,605/MST (JPY) 
Lee et al. 2014 China Not Specified Erlotinib vs. Gefitinib OPTIMAL, IPASS, NEJGSG, WJTOG Erlotinib vs. Gefitinib: $62,419/QALY
Tan et al. 2018 Singapore Payer Afatinib vs. PC Lux-Lung 3
Afatinib vs. PC: SG$137,648/QALY and 
SG$109,172/LY
Ting et al. 2015 US Societal Erlotinib vs. Afatinib, PC EURTAC, Lux-Lung 3
Erlotinib vs. Afatinib: $61,809/QALY
Erlotinib vs. PC: $40,106/QALY
Wang et al. 2018 China Payer Afatinib vs. Gefitinib Lux-Lung 7
ITT: $9820/QALY
Exon Leu858Arg: $18,530/QALY
Exon 19 Del: $1586/QALY
Wen et al. 2018 China Payer GC vs. Erlotinib OPTIMAL, ENSURE GC vs. Erlotinib: $174,808/QALY
Yang et al. 2020 Taiwan Payer Afatinib, Erlotinib, Gefitinib
Records from National Cheng Kung 
University Hospital
Afatinib dominated by Erlotinib





Chapter 3: Real-World Effectiveness of Nivolumab in 
Patients with Non-Small-Cell Lung Cancer: A 
Systematic Review and Meta-Analysis 
3.1. Abstract 
Background: The effectiveness of PD-1 checkpoint inhibitors for non-small-cell lung cancer 
under real-world clinical settings remains uncertain. Materials & methods: Systematic searches 
of PubMed, EMBASE and Web of Science were conducted. Random-effects models were used 
to estimate pooled median overall survival and progression-free survival estimates. Results: 36 
studies of nivolumab were included for narrative synthesis and 11 of these studies were included 
for meta-analysis. Age, sex, histology and prior lines of treatment did not affect survival 
outcomes, while Eastern Cooperative Oncology Group Performance Status and brain metastasis 
were inversely associated with survival. In the meta-analysis, nivolumab was associated with 9.6 
months (95% CI: 8.4–10.9) of overall survival and 2.6 months (95% CI: 1.6–3.6) of progression-
free survival. Conclusion: Very-low-certainty evidence suggested the real-world effectiveness of 
nivolumab was consistent with those observed in the clinical trials.  
3.2. Introduction 
The epidemiology of lung cancer is specified in Chapter 2 of this thesis. While many first-line 
treatments for NSCLC are available, the number of second-line therapies remains limited. Recent 
development of immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 pathway have 
shown increased survival over standard of care docetaxel-based chemotherapy in the second-line 
treatment of persons with advanced/metastatic NSCLC (Borghaei et al., 2015; Brahmer et al., 




Nivolumab (Opdivo; Bristol-Myers Squibb, NJ, USA) was the first ICI to be approved by the US 
Food and Drug Administration (FDA) for treating patients with advanced NSCLC following 
first-line platinum-based chemotherapy. In the CheckMate-017 trial, nivolumab was associated 
with improved OS, PFS and ORR compared to docetaxel in patients with pre-treated squamous 
lung carcinoma (Brahmer et al., 2015). Similarly, in the CheckMate-057 trial, conducted in 
recurrent nonsquamous patients, nivolumab was shown to improve OS and ORR over docetaxel, 
but not PFS (Borghaei et al., 2015). In the CheckMate-026 trial, administration of nivolumab as 
first-line treatment in patients with PD-L1-positive NSCLC was associated with similar OS and 
PFS, and lower ORR compared with platinum-based chemotherapy (Carbone et al., 2017).  
Although randomized controlled trials (RCTs) are the gold-standard approach to assessing the 
safety and efficacy of therapeutic interventions, trial results often do not reflect the effectiveness 
of therapy in clinical practice. The gap between efficacy and effectiveness may be bridged by 
real-world studies in clinical practice, which often complement RCTs by investigating a wider 
spectrum of patients with more diverse demographic profiles, prognoses and comorbidities. We 
undertook this systematic review and meta-analysis to evaluate the effectiveness of nivolumab 
therapy in real-world settings and to compare the results in these settings with the findings of 
RCTs. 
3.3. Materials and Methods 
3.3.1. Search Strategy 
The systematic review protocol was registered with the International Prospective Register of 
Systematic Reviews (PROSPERO) on 5 April 2019 (CRD 42019127837). This review was 




Analyses (PRISMA) guideline (Moher et al., 2009). We searched PubMed, EMBASE and Web 
of Science to identify studies published between March 2015 and March 2019. The March 2015 
start date coincided with the FDA’s approval of the first immunotherapy (nivolumab) for treating 
NSCLC. A medical librarian helped develop the search strategy and tailor it for each database. 
Reference lists of all eligible studies were searched to find additional publications. Only English-
language studies published in peer-reviewed journals were considered for inclusion (Appendix 
A) 
3.3.2. Study Selection 
We included any type of observational study reporting OS or PFS in clinical practice. 
Interventions included atezolizumab, nivolumab or pembrolizumab for treating NSCLC, 
regardless of whether the treatment was used as first- or second-line therapy, or in some other 
therapeutic manner. We excluded case reports, RCTs, conference abstracts, letters to the editor, 
narrative reviews and systematic reviews/meta-analyses.  
Article titles and abstracts were screened independently by two reviewers (YJ Kim and D Shah) 
to identify citations that might satisfy the eligibility criteria. These citations advanced to full-text 
screening, where they were again independently evaluated by the two reviewers (YJ Kim and D 
Shah). The reviewers resolved discrepancies through consensus or referred articles to a third 
reviewer (S Horton) for arbitration in the absence of consensus. Additional citations identified 
through the reference lists of included articles were screened as previously described. 
3.3.3. Data Extraction 
Data extraction was conducted independently by two reviewers (YJ Kim and D Shah) using a 




or by a third reviewer (S Horton). We extracted the following data from the studies: author, year 
of publication, country, intervention, design, study population, sample size, age, sex, smoking 
status, line of therapy, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), 
stage, histological subtype, metastasized sites, biomarker summary, follow-up period, treatment 
cycles, median OS and median PFS with 95% CI, and proportion of adverse events. 
3.3.4. Quality Assessment 
Risk of bias was assessed using the Newcastle–Ottawa Scale (NOS) – Cohort Studies (Wells et 
al., 2019). To assess included case-series, we modified the NOS and excluded the sections 
related to ‘selection of the nonexposed cohort’ and ‘comparability of the cohort’; the scores on 
the modified NOS ranged from zero stars (high risk of bias) to six stars (low risk of bias). Risk of 
bias assessment was performed independently by the two reviewers (YJ Kim and D Shah). 
Discrepancies were resolved by consensus or referred to a third reviewer (S Horton) for 
arbitration in the absence of consensus. The Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) approach (Dijkers, 2013) was used to assess the 
certainty of evidence for OS and PFS. 
3.3.5. Data Synthesis and Analysis 
A narrative synthesis was conducted on all included studies, with the synthesis being stratified 
by variables including age, sex, histology, prior lines of treatment, brain metastasis, and ECOG-
PS. Separate random effects meta-analyses following McGrath et al.’s procedure (McGrath et al., 
2020; McGrath et al., 2019) were conducted for median OS and PFS. Studies were meta-
analyzed if they satisfied the following criteria: reported on the administration of nivolumab at 3 




of quantitative data to permit inclusion in meta-analysis (e.g., presented Kaplan–Meier curves to 
permit us obtain study-specific minimum and maximum values to estimate pooled median OS 
and PFS). Furthermore, in the meta-analysis, we included studies with samples drawn from 
broad-based populations, and we excluded studies using samples chosen from narrowly defined 
population.  
Statistical heterogeneity was assessed using the I2 statistic and tested with Cochran’s Q statistic 
and its associated p-value. Substantial heterogeneity was considered to be present when I2 >50% 
and p < 0.10. We decided a priori to assess publication bias with funnel plots if ten or more 
articles were included in a meta-analysis. The meta-analyses were conducted using the ‘meta-
median’ package in R v3.6.0 (The R Foundation for Statistical Computing, Vienna, Austria). 
3.4. Results 
3.4.1. Search Results 
The flow chart detailing study selection is depicted in Figure 4. The literature search identified 
1848 citations from the three databases. After removing duplicates and screening titles, abstracts, 
and full texts, we identified 36 studies for inclusion in the review and 11 studies for meta-
analysis. Our literature search did not yield any articles on atezolizumab and identified only one 





Figure 4. Flow diagram of study selection  
 
3.4.2. Study Characteristics and Quality Assessment 
The characteristics of the included studies are shown in Table 4. The studies were retrospective 




cohort (n = 3). All case-series studies assessed outcomes associated with nivolumab. One cohort 
study compared effectiveness between nivolumab and docetaxel (Calpe-Armero et al., 2017), 
while another compared effectiveness between nivolumab and pembrolizumab (Ksienski et al., 
2019). The third cohort study compared effectiveness of nivolumab at a standard-dose of 3 
mg/kg per 2 weeks to a low-dose of 20/100 mg per 3 weeks (Yoo et al., 2018). The studies were 
carried out in multicenter (n = 21) or single center (n = 15) settings.  
The studies contained a total of 6504 participants, with sample sizes ranging from 19 to 1588 
(mean = 181). The mean or median ages ranged from 58 to 71 years. The percentage of males 
enrolled in the 36 studies ranged from 39 to 100% (mean = 66.6%). The included studies 
generally had low risk of bias, with most scoring 4 to 6 on the NOS among case-series and 6 to 7 















Prior Lines of 
Treatment (%) 
Site of Metastasis 
(%) 
Median OS 
(95% CI),  
Months 
Median PFS  







3mg/kg per 2 
weeks 
Adenocarcinoma - 60 
Squamous - 35 
NOS - 5 
188 1 – 117 (62) 
2 – 45 (24) 
≥3 – 26 (14) 
CNS – 42 (22) 
 
12.85 months 
(95%CI: 9.07 - 
16.62) 
4.83 months 
(95%CI: 3.69 - 
5.97) 
Bagley et al. 2017/  
US 
Nivolumab 
3mg/kg per 2 
weeks 
Squamous - 24 
Non-squamous - 76 
175 1 – 94 (54) 
2 – 44 (25) 
≥3 – 37 (21) 
Bone – 86 (49) 
Brain – 55 (31) 
















Squamous - 41.4 
Large cell - 1.7 
Adenosquamous - 1.7 
58 1 – 20 (34.5) 
2 – 27 (46.6) 
≥3 – 11 (18.9) 













per 3 weeks 
Nivolumab -  
Squamous - 21 
Non-squamous - 79 
Docetaxel -  
Squamous - 21 




NR NR Nivolumab -  
Not achieved 




Nivolumab -  
2.76 months 
(95%CI: 1.28-9.87) 
Docetaxel -  
2.0 months (95%CI: 
1.58-2.50) 
Costantini et al. 2018/ 
France 
Nivolumab 
3mg/kg per 2 
weeks 
Squamous - 28 
Adenocarcinoma - 61 
Giant - 7 
303 1 – 120 (40) 
2 – 88 (29) 
≥3 – 94 (31) 
Lung – 120 (40) 
Pleura – 88 (29) 
CNS – 62 (20) 
Liver – 48 (16) 
Adrenal Gland – 
54 (18) 




2.6 months (95%CI: 
2.1-3.5) 
Crino et al. 2019/ 
Italy 
Nivolumab 
3mg/kg per 2 
weeks 
Non-squamous - 100 1588 1 – 378 (24) 
2 – 562 (36) 
≥3 – 639 – (40) 
Unknown – 9 
(1) 
CNS – 409 (26) 
Bone – 327 (21) 
Liver – 626 (39) 
11.3 months 
(95%CI: 10.2 - 
12.4) 
3.0 months (95%CI: 













Prior Lines of 
Treatment (%) 
Site of Metastasis 
(%) 
Median OS 
(95% CI),  
Months 
Median PFS  
(95% CI),  
Months 
Diem et al. 2017/ 
Switzerland 
Nivolumab 
3mg/kg per 2 
weeks 
Squamous - 35 
Adenocarcinoma - 58 
52 0 – 2 (4) 
1 – 29 (56) 
2 – 13 (25) 
≥3 – 8 (16) 
Bone – 17 (33) 
Liver – 17 (33) 
Lung – 15 (29) 
Brain – 15 (29) 
Adrenal – 10 (19) 
Pleura – 9 (17) 
Soft tissue – 6 (12) 
9.6 months 
(95%CI: 6-14) 
2.1 months (95%CI: 
1.8-6.4) 
Dudnik et al. 2018/ 
Israel 
Nivolumab  
3mg/kg per 2 
weeks 
Squamous - 23 
Non-squamous - 70 
Other - 6 
NR - 1 
260 0 – 15 (6) 
1 – 167 (64) 
≥2 – 68 (26) 
NR – 10 (4) 
Brain – 55 (21) 




2.8 months (95%CI: 
1.8 - 7.7) 
Dumenil et al. 2018/ 
France 
Nivolumab 
3mg/kg per 2 
weeks 
Squamous - 25 
Adenocarcinoma - 70 
Others - 5 
67 NR CNS – 11 (16) 6.3 months (IQR 
- 3.1 - 13.5) 
3 months (IQR - 1.6 
- 6.6) 
Facchinetti et al. 2018/ 
Italy 
Nivolumab 
3mg/kg per 2 
weeks 
Squamous - 48 
Non-squamous - 52 
54 NR Lymph Node – 48 
(88) 
Liver – 8 (15) 
Bone – 16 (30) 
Adrenal Gland – 8 
(17) 
Brain – 7 (13) 
Contralateral Lung 
– 27 (50) 
Pleura – 19 (38) 




2.5 months (95%CI: 
1.5-3.5) 
Fiorica et al. 2018/ 
Italy 
Nivolumab 
3mg/kg per 2 
weeks 
Squamous - 54 
Non-squamous - 46 
35 1 – 27 (77) 
2 – 5 (14) 
3 – 3 (9) 
Lung – 16 (46) 
Bone – 8 (23) 
Lymph Node – 12 
(34) 





Fujimoto et al. 2019/ 
Japan 
Nivolumab 
3mg/kg per 2 
weeks 
Squamous - 24 
Non-squamous - 66 
NOS - 6 
Other - 4 
542 1 – 180 (33) 
2 – 136 (25) 
≥3 – 226 (42) 
NR 16.1 months 2.6 months 
Fukui et al. 2019/ 
Japan 
Nivolumab 
3mg/kg per 2 
weeks 
Squamous - 31 
Adenocarcinoma - 63 
NOS - 6 
52 1 – 22 (42) 
2 – 15 (29) 
≥3 – 15 (29) 
Brain – 8 (15) 
Lung – 22 (42) 
Liver – 10 (19) 
Bone – 16 (31) 














Prior Lines of 
Treatment (%) 
Site of Metastasis 
(%) 
Median OS 
(95% CI),  
Months 
Median PFS  







3mg/kg per 2 
weeks 
Squamous - 23 
Non-squamous - 77 
175 1 – 65 (37) 
2 – 66 (38) 
≥3 – 44 (25) 
Brain – 38 (22) 
Lung – 115 (67) 
Liver – 39 (23) 
Bone – 67 (39) 
Adrenal Gland – 
31 (18) 
Lymph Node – 
100 (58) 







Garassino et al. 2018/ 
Italy 
Nivolumab 
3mg/kg per 2 
weeks 
Squamous - 100 371 1 – 162 (44) 
2 – 120 (32) 
≥3 – 89 (24) 
CNS – 37 (10) 
Liver – 63 (17) 
Bone – 120 (32) 
7.9 months 
(95%CI: 6.2 - 
9.6) 
4.2 months (95%CI: 
3.4 - 5.0) 
Grossi et al. 2018/ 
Italy 
Nivolumab 
3mg/kg per 2 
weeks 
Squamous - 100 371 1 – 162 (44) 
2 – 120 (32) 
≥3 – 89 (24) 
Brain – 37 (10) 
Liver – 63 (17) 
Bone – 120 (32 
7.9 months 
(95%CI: 6.2 - 
9.6) 
4.2 months (95%CI: 
3.4 - 5.0) 
Haratani et al. 2017/ 
Japan 
Nivolumab 
3mg/kg per 2 
weeks 
Pre-TKI: 
Adenocarcinoma - 96 
Squamous - 4 
Post-TKI: 
Adenocarcinoma - 72 
NOS - 12 
Not examined - 16 
25 1 – 28 (33) 
2 – 21 (25) 
≥3 – 36 (42) 
CNS – 14 (16) Not reached 1.5 months (95%CI: 
1.3-2.8) 
Juergens et al. 2018/ 
Canada 
Nivolumab 
3 mg/kg per 2 
weeks 
Squamous - 26.3 
Non-squamous - 73.1 
Others - 0.6 
472 1 – 209 (44) 
2 – 138 (29) 
≥3 – 125 (27) 
CNS – 62 (13) 12.0 months 
(95%CI: 11.0 - 
13.9) 
NR 
Kataoka et al. 2018/ 
Japan 
Nivolumab 
3mg/kg per 2 
weeks 
Squamous - 24 
Non-squamous - 76 
189 1 – 14 (7) 
2 – 32 (17) 
≥3 - 143 (76) 
NR NR 2.4 months 
Kiriu et al. 2018/ 
Japan 
Nivolumab 
3mg/kg per 2 
weeks 
Squamous - 32 
Adenocarcinoma - 53 
Other - 15 
19 1 – 5 (26) 
2 – 9 (47) 
≥3 – 5 (26) 
NR 10.8 months iNLR (increase in 
NLR) - 1.8 months 
sNLR (stable or 
decreased NLR)- 
9.3 months 
Kobayashi et al. 2018/ 
Japan 
Nivolumab 




Squamous - 28.9 
NOS - 6.3 
142 1 – 57 (40) 
≥2 – 85 (60) 














Prior Lines of 
Treatment (%) 
Site of Metastasis 
(%) 
Median OS 
(95% CI),  
Months 
Median PFS  
(95% CI),  
Months 
Ksienski et al. 2019/ 
Canada 
Nivolumab 




2mg/kg per 3 
weeks 
Nivolumab: 
Squamous - 25.7 
Non-squamous - 74.3 
Pembrolizumab: 
Squamous - 19.5 







0 – 4 (2) 
1 – 165 (72) 
≥2 – 61 (26) 
Pembrolizumab: 
0 – 17 (42) 
1 – 19 (46) 
≥2 – 5 (12) 
Nivolumab: 
Brain – 30 (13) 
Liver – 28 (12) 
Pembrolizumab: 
Brain – 6 (15) 















Lesueur et al. 2018/ 
France 
Nivolumab Adenocarcinoma - 
32.7 
Squamous - 62.5 
Other - 4.8 
104 0-1 – 57 (55) 
2 - 31 (30) 
≥3 – 16 (15) 
Brain – 46 (44) 11.1 months 
(95%CI: 5.8 - 
16.5) 
2.7 months (95%CI: 






3mg/kg per 2 
weeks 
Squamous - 59.7 
Non-squamous - 38 
221 NR Lung – 115 (52) 
Lymph Node – 72 
(33) 
Bone – 69 (31) 
Liver – 41 (19) 
Brain – 22 (10) 
9.7 months 
(95% CI: 7.6 - 
11.8) 
5.3 months (95% 
CI: 3.2-7.3) 
Montana et al. 2019/ 
France 
Nivolumab 
3 mg/kg per 2 
weeks 
Squamous - 21.4 
Non-squamous - 78.6 
98 0-1 – 44 (45) 
≥2 – 54 (55) 
NR 6.34 months 
(95% CI: 4.11 - 
10.88) 
1.84 months (95% 
CI: 1.68 - 2.73) 
Sabatier et al. 2018/ 
France 
Nivolumab 
3mg/kg per 2 
weeks 
Squamous - 37 
Non-squamous - 63 
30 1 – 20 (67) 
2 – 4 (13) 
≥3 – 6 (20)  
NR 7.1 months 
(95%CI: 4.9 - 
9.4) 
3.3 months (95%CI: 
2.7 - 3.9) 
Sato et al. 2018/ 
Japan 
Nivolumab 
3mg/kg per 2 
weeks 
Squamous - 26 
Non-squamous - 74 
38 NR NR NR 2.9 months (95%CI: 
1.55 - NR) 
Schmid et al. 2018/ 
Switzerland 
Nivolumab 
3mg/kg per 2 
weeks 
Squamous - 35 
Adenocarcinoma - 58 
52 0 – 2 (4) 
1 – 29 (56) 
2 – 13 (25) 
≥3 – 8 (16) 
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(%) 
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(95% CI),  
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(95% CI),  
Months 








Squamous cell - 22.2 
Mixed - 6.5 
Unspecified - 4.8 
248 0–2 (0.8%) 
1–185 (74.6%) 
2 - 44 (17.7%) 
3 – 14 (5.7%) 
>3 – 3 (1.2%) 
Brain – 56 (23) 10.0 months 
(95% CI: 6.65-
13.35) 
2.6 months (95% 
CI: 2.38 - 2.82) 
Sekine et al. 2018/ 
Japan 
Nivolumab 
3mg/kg per 2 
weeks 
Squamous - 11.5 
Adenocarcinoma - 
73.6 
Other - 14.9 
87 0 – 2 (2) 
1 – 23 (27) 
2 – 34 (39) 
≥3 – 28 (32) 
NR 12.5 months 
(95%CI: 8.8-
13.7) 







3 mg/kg per 2 
weeks 
Squamous - 16.89 
Non-squamous - 
83.11 
77 0 – 3 (4) 
1 – 43 (56) 
2 – 14 (18) 
≥3 – 17 (22) 
NR 8 months (NR) 4 months (NR) 
Shiroyama et al. 2018/ 
Japan 
Nivolumab 
3mg/kg per 2 
weeks 
Squamous - 20.4 
Non-squamous - 79.6 
201 Median – 2 NR NR 2.9 months (95%CI: 
2.1-3.7) 
Takeda et al. 2018/ 
Japan 
Nivolumab 
3mg/kg per 2 
weeks 
Squamous - 30 
Adenocarcinoma - 70 
30 1 – 8 (27) 
2 – 9 (30) 
≥3 – 13 (43) 
NR NR 2.6 months (95%CI: 
1.3-4.9) 
Tiu et al. 2018/ 
US 
Nivolumab 
3mg/kg per 2 
weeks 
Squamous - 13 
Adenocarcinoma - 71 
Mixed - 5 
Other - 11 
38 NR Contralateral lobe 
– 9 (24) 
Pleural nodules – 6 
(16) 
Pleural/Pericardial 
Effusion – 8 (21) 
Extrathoracic 
Organs – 25 (66) 
21.4 months 
(95%CI: 13.5 - 
27.4) 
6.3 months (95%CI: 













Prior Lines of 
Treatment (%) 
Site of Metastasis 
(%) 
Median OS 
(95% CI),  
Months 
Median PFS  
(95% CI),  
Months 
Tournoy et al. 2018/ 
Belgium 
Nivolumab Squamous - 26.6 
Non-squamous - 73.4 
267 1 – 138 (51.7) 
2 – 87 (32.6) 
3 – 32 (12.0) 
4 – 8 (3.0) 
5 – 2 (0.7) 
Pulmonary – 140 
(52) 
Bone – 115 (43) 
Extrathoracic 
lymph nodes – 64 
(24) 
Liver – 55 (21) 
Brain – 46 (17) 





3.7 months (95%CI: 
2.9-4.5) 




3mg/kg per 2 
weeks 
Low dose: 
100 or 20mg 
every 3 week 
Adenocarcinoma - 
61.7 
Squamous - 14.9 
Other - 23.4 
47 Overall: 
1 – 18 (38) 
2 – 16 (34) 
≥3 – 13 (28) 
Standard: 
1 – 13 (45) 
2 – 10 (34) 
3 – 6 (21) 
Low-dose: 
1 – 5 (28) 
2 – 6 (29) 














1.1 months (95%CI: 
0.8-3.0) 
Standard-dose: 
1.0 months (95%CI: 
0.6-1.7) 
Low-dose: 
3.0 months  
(95% CI: 0.8-NR) 




3.4.3. Overall Survival 
Thirty studies reported OS outcomes (Areses Manrique et al., 2018; Bagley et al., 2017; Brustugun 
et al., 2017; Calpe-Armero et al., 2017; Costantini et al., 2018; Crinò et al., 2019; Diem et al., 2017; 
Dudnik et al., 2018; Dumenil et al., 2018; Facchinetti et al., 2018; Fiorica et al., 2018; Fleischman 
et al., 2016; Fujimoto et al., 2019; Garassino et al., 2018; Garde-Noguera et al., 2018; Grossi et al., 
2018; Haratani et al., 2017; Juergens et al., 2018; Kiriu et al., 2018; Kobayashi et al., 2018; 
Ksienski et al., 2019; Lesueur et al., 2018; Merino Almazán et al., 2019; Montana et al., 2019; 
Sabatier et al., 2018; Schmid et al., 2018; Schouten et al., 2018; Sekine et al., 2018; Shamai & 
Merimsky, 2018; Tiu et al., 2018; Tournoy et al., 2018; Yoo et al., 2018). The median follow-up 
period was 1 year or less in ten studies (Crinò et al., 2019; Fiorica et al., 2018; Garassino et al., 
2018; Grossi et al., 2018; Juergens et al., 2018; Ksienski et al., 2019; Sabatier et al., 2018; Schouten 
et al., 2018; Takeda et al., 2018; Yoo et al., 2018) and >1 year in six studies (Bagley et al., 2017; 
Calpe-Armero et al., 2017; Diem et al., 2017; Dumenil et al., 2018; Ksienski et al., 2019; Sato et al., 
2018). In studies with median follow-up periods of <1 year, the median OS associated with 
nivolumab ranged from 7.1 (Sabatier et al., 2018) to 21.4 months (Tiu et al., 2018). In studies with 
median follow-up periods of ≥1 year, the median OS ranged from 4.0 (Facchinetti et al., 2018) to 
11.9 months (Schmid et al., 2018). Median OS reported by Tiu et al. (21.4 months) was 
substantially longer than what authors reported in the other studies (Tiu et al., 2018). In two studies, 
half of the participants did not experience the outcome by the end of the study and thus, median OS 
associated with nivolumab was not reached (NR) (Calpe-Armero et al., 2017; Yoo et al., 2018). 
Twenty-seven studies were case-series and three were cohort studies (Calpe-Armero et al., 2017; 
Ksienski et al., 2019; Yoo et al., 2018). In case-series studies of nivolumab, median OS ranged from 
5.7 (Facchinetti et al., 2018) to 21.4 months (Tiu et al., 2018). In cohort studies, Ksienski et al. 
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reported median OS of 9.2 (95% CI: 7.8–12.4) and 13.5 months (95% CI: 10.62–NR) for nivolumab 
and pembrolizumab, respectively, while it was NR in a study by Calpe-Armero et al. (Calpe-
Armero et al., 2017; Ksienski et al., 2019). Yoo et al. reported median OS of 8.2 (95% CI: 3.1–NR) 
and 12.5 months (95% CI: 7.0–NR) for standard and low-dose nivolumab therapy, respectively 
(Yoo et al., 2018). 
Summary of median OS stratified by age, sex, ECOG-PS, histology, line of therapy and brain 
metastasis can be found in the Appendix C. For the most part, age, sex, histology and line of 
therapy did not appear to affect median OS. Exceptions were one study where male sex was 
negatively associated with OS (hazard ratio [HR]: 1.67; 95% CI: 1.05–2.64) (Grossi et al., 2018). 
Two other studies identified a statistically significant improvement in OS for persons with 
squamous histology compared with nonsquamous histology, with adjusted HR (aHRs) of 0.47 (95% 
CI: 0.25–0.91) (Schouten et al., 2018) and 0.59 (95% CI: 0.38–0.91) (Merino Almazán et al., 2019), 
respectively.  
Statistically significant differences in survival were observed according to ECOG-PS. Eight studies 
reported median OS stratified by ECOG-PS (Areses Manrique et al., 2018; Dudnik et al., 2018; 
Facchinetti et al., 2018; Juergens et al., 2018; Merino Almazán et al., 2019; Montana et al., 2019; 
Schouten et al., 2018; Tournoy et al., 2018) with greater survival generally found in persons with 
lower ECOG-PS. The highest median OS was seen among patients with an ECOG-PS of 0 because 
the median OS was NR in two studies (Areses Manrique et al., 2018; Tournoy et al., 2018). The 
lowest OS was reported among patients with ECOG-PS of ≥2, with a median OS of 1.8 months 
(Facchinetti et al., 2018). Brain metastasis was another factor significantly associated with OS. Six 
studies reported median OS stratified by brain metastasis (Areses Manrique et al., 2018; Crinò et al., 
2019; Dudnik et al., 2018; Facchinetti et al., 2018; Juergens et al., 2018; Schouten et al., 2018). 
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Compared with patients having no brain metastases, shorter median OS was reported for those with 
brain metastases (Areses Manrique et al., 2018; Crinò et al., 2019; Dudnik et al., 2018; Juergens et 
al., 2018; Schouten et al., 2018). 
3.4.4. Progression-free Survival 
Thirty-three studies reported median PFS (Areses Manrique et al., 2018; Bagley et al., 2017; Calpe-
Armero et al., 2017; Costantini et al., 2018; Crinò et al., 2019; Diem et al., 2017; Dudnik et al., 
2018; Dumenil et al., 2018; Facchinetti et al., 2018; Fujimoto et al., 2019; Fukui et al., 2019; 
Garassino et al., 2018; Garde-Noguera et al., 2018; Grossi et al., 2018; Haratani et al., 2017; 
Kataoka et al., 2018; Kiriu et al., 2018; Kobayashi et al., 2018; Ksienski et al., 2019; Lesueur et al., 
2018; Merino Almazán et al., 2019; Montana et al., 2019; Sabatier et al., 2018; Sato et al., 2018; 
Schmid et al., 2018; Schouten et al., 2018; Sekine et al., 2018; Shamai & Merimsky, 2018; 
Shiroyama et al., 2018; Takeda et al., 2018; Tiu et al., 2018; Tournoy et al., 2018; Yoo et al., 2018). 
It is worth noting that as all included studies were observational in nature, PFS was assessed 
through sets of pre-defined proxy measures (e.g., initiation of 2L treatment) rather than assessment 
as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) criteria as set 
forth in clinical trials. Nineteen of the thirty-three studies (Calpe-Armero et al., 2017; Costantini et 
al., 2018; Crinò et al., 2019; Dudnik et al., 2018; Facchinetti et al., 2018; Fukui et al., 2019; 
Garassino et al., 2018; Grossi et al., 2018; Haratani et al., 2017; Kataoka et al., 2018; Ksienski et 
al., 2019; Lesueur et al., 2018; Sabatier et al., 2018; Sato et al., 2018; Schmid et al., 2018; Schouten 
et al., 2018; Shiroyama et al., 2018; Tiu et al., 2018; Yoo et al., 2018) reported median follow-up 
times, which were <1 year in 13 studies (Calpe-Armero et al., 2017; Crinò et al., 2019; Fukui et al., 
2019; Garassino et al., 2018; Grossi et al., 2018; Haratani et al., 2017; Kataoka et al., 2018; 
Ksienski et al., 2019; Sabatier et al., 2018; Sato et al., 2018; Schouten et al., 2018; Tiu et al., 2018; 
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Yoo et al., 2018) and ≥1 year in six studies (Costantini et al., 2018; Dudnik et al., 2018; Facchinetti 
et al., 2018; Lesueur et al., 2018; Schmid et al., 2018; Shiroyama et al., 2018). Median PFS ranged 
from 1.0 (Yoo et al., 2018) to 6.3 months (Tiu et al., 2018) in studies with median follow-ups of ≥1 
year.   
Thirty studies were case-series and three were cohort studies (Calpe-Armero et al., 2017; Ksienski 
et al., 2019; Yoo et al., 2018). Among case-series, the median PFS ranged from 1.5 (Haratani et al., 
2017) to 6.3 months (Tiu et al., 2018). Among cohort studies, Ksienski et al. reported median PFS 
of 5.7 months (95% CI: 4.1–8.8) and 13.5 months (95% CI: 8.2–NR) for nivolumab and 
pembrolizumab, respectively (Ksienski et al., 2019). Calpe-Armero et al. reported median PFS of 
2.76 months (95% CI: 1.28–9.87) for nivolumab and 2.0 months (95% CI: 1.58– 2.50) for docetaxel 
(Calpe-Armero et al., 2017). Yoo et al. reported median PFS of 1.1 months (95% CI: 0.8–3.0) for 
the overall sample, 1.0 months (95% CI: 0.6–1.7) for patients who received the standard dose of 
nivolumab, and 3.0 months (95% CI: 0.8–NR) for patients who received lower doses of nivolumab 
(Yoo et al., 2018). 
No statistically significant differences were observed among studies reporting median PFS for 
nivolumab stratified by age, sex, histology and brain metastasis (Appendix D). Statistically 
significant differences in median PFS were observed in subgroups defined by ECOG-PS. Four 
studies reported median PFS stratified by ECOG-PS, with higher ECOG-PS having negative 
association with median PFS (Dumenil et al., 2018; Merino Almazán et al., 2019; Montana et al., 
2019; Schouten et al., 2018). The median PFS ranged from 2.3 (Montana et al., 2019) to 7.6 months 
(Merino Almazán et al., 2019) for ECOG-PS of 0–1, and 1.1 (Dumenil et al., 2018) to 2.1 months 
(Schouten et al., 2018) for ECOG-PS of ≥2. Seven studies reported aHRs comparing ECOG-PS of 
≥2 with ECOG-PS of <2 (Bagley et al., 2017; Diem et al., 2017; Dumenil et al., 2018; Kataoka et 
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al., 2018; Lesueur et al., 2018; Schouten et al., 2018; Shiroyama et al., 2018); ECOG-PS was 
statistically significant in four studies (Dumenil et al., 2018; Kataoka et al., 2018; Lesueur et al., 
2018; Shiroyama et al., 2018) with aHRs ranging from 1.60 (95% CI: 1.10–2.33) (Shiroyama et al., 
2018) to 5.17 (95% CI: 1.99–13.43) (Dumenil et al., 2018). 
3.4.5. Safety 
Twenty-two studies reported information on treatment-related adverse events (TRAEs) (Areses 
Manrique et al., 2018; Bagley et al., 2017; Brustugun et al., 2017; Crinò et al., 2019; Dudnik et al., 
2018; Dumenil et al., 2018; Fukui et al., 2019; Garassino et al., 2018; Garde-Noguera et al., 2018; 
Kobayashi et al., 2018; Ksienski et al., 2019; Lesueur et al., 2018; Merino Almazán et al., 2019; 
Montana et al., 2019; Sabatier et al., 2018; Sato et al., 2018; Schouten et al., 2018; Sekine et al., 
2018; Shamai & Merimsky, 2018; Takeda et al., 2018; Tiu et al., 2018; Tournoy et al., 2018). A 
total of 2679 (58.4%) of all 4585 patients enrolled in the 22 studies experienced TRAEs of any 
grade; grade 3 and 4 TRAEs were reported in 440 (10.0%) patients (Areses Manrique et al., 2018; 
Bagley et al., 2017; Brustugun et al., 2017; Crinò et al., 2019; Dudnik et al., 2018; Dumenil et al., 
2018; Fukui et al., 2019; Garassino et al., 2018; Garde-Noguera et al., 2018; Grossi et al., 2018; 
Kobayashi et al., 2018; Ksienski et al., 2019; Lesueur et al., 2018; Merino Almazán et al., 2019; 
Montana et al., 2019; Sabatier et al., 2018; Sato et al., 2018; Schouten et al., 2018; Tiu et al., 2018; 
Tournoy et al., 2018). The most common TRAEs associated with nivolumab were fatigue/asthenia 
(reported in 11.8% of the 4585 patients), rash/pruritis (6.9%), hypothyroidism/hyperthyroidism 
(5.3%), diarrhea/colitis (5.3%) and decreased appetite/anorexia (3.6%; Figure 5). The most common 
≥grade 3 TRAEs were fatigue/asthenia (1.5%), pneumonitis (1.4%), diarrhea/colitis (0.9%), 




Figure 5 Incidence of most common treatment-related adverse events associated with 
nivolumab 
 
3.4.6. Meta-analysis of OS 
Ten studies were included in the meta-analysis for OS (Brustugun et al., 2017; Costantini et al., 
2018; Crinò et al., 2019; Dudnik et al., 2018; Fiorica et al., 2018; Grossi et al., 2018; Juergens et al., 
2018; Ksienski et al., 2019; Schouten et al., 2018; Yoo et al., 2018). The pooled estimate showed 
that nivolumab was associated with a median OS of 9.6 months (95% CI: 8.4–10.9; p < 0.0001) 




Figure 6 Pooled analysis of overall survival associated with nivolumab 
 
3.4.7. Meta-analysis of PFS 
Five studies were included in the meta-analysis for PFS (Costantini et al., 2018; Grossi et al., 2018; 
Kataoka et al., 2018; Schouten et al., 2018; Yoo et al., 2018). The pooled estimate showed that 
nivolumab was associated with a median PFS of 2.6 months (95% CI: 1.6–3.6; p < 0.0001); (Figure 




Figure 7 Pooled analysis of progression-free survival associated with nivolumab 
 
3.4.8. Publication Bias 
Visual inspection of the funnel plot for OS suggests that publication bias is present (Appendix E). 
The asymmetry of the funnel plot suggests that smaller studies with lower OS are not being 
published. 
3.4.9. GRADE 
Overall evidence was assessed using the GRADE approach for both OS and PFS (Dijkers, 2013). 
The certainty of evidence was very low for both OS and PFS because of the observational nature of 
the included studies and inconsistency (Appendix F). 
3.5. Discussion 
ICIs targeting the PD-1/PD-L1 pathway are possible alternatives to docetaxel as means of treating 
advanced/metastatic NSCLC in second-line settings. Results from the CheckMate-017 and 
CheckMate-057 RCTs demonstrated that nivolumab was associated with longer median survival 
outcomes compared with docetaxel, and additional studies showed that treatment with nivolumab 
continued to yield positive results after 2–3-years of follow-up (Borghaei et al., 2015; Brahmer et 
al., 2015; Horn et al., 2017; Vokes et al., 2018). However, the effectiveness of nivolumab in real-
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world settings, outside the domain of RCTs, remains unclear. Thus, we conducted this systematic 
review and meta-analysis to evaluate the effectiveness of nivolumab in real-world clinical practice 
settings, and to assess whether its effectiveness is comparable with the results seen in published 
RCTs. 
Our meta-analysis indicated that nivolumab was associated with median OS and PFS of 9.6 and 2.6 
months, respectively. The OS estimate fell below the median OS reported in the CheckMate-057 
trial (12.2 months [95% CI: 9.7–15.0]) and EVIDENS study (11.2 months [95% CI: 10.0–12.4]), 
but it was higher than what was reported in the CheckMate-017 trial (9.2 months [95% CI: 7.3–
13.3]). The PFS estimate from the meta-analysis was similar to the CheckMate-057 trial (2.3 
months [95%CI: 2.2-3.3]) and EVIDENS study (2.8 months [95%CI: 2.6-3.2]); however, it was 
below the estimate reported in the CheckMate-017 trial (3.5 months [95%CI: 2.1-4.9]). Moreover, 
the OS and PFS estimates were comparable with the pooled results obtained from the 
CheckMate017 and CheckMate-057 trials; Vokes et al. reported pooled OS and PFS estimates of 
11.1 and 2.56 months, respectively (Vokes et al., 2018). However, the certainty of the real-world 
evidence was very low, according to GRADE; therefore, future evidence may change the 
conclusions emerging from the current evidence about OS and PFS in real-world settings. 
To the best of our knowledge, this was the first systematic review and meta-analysis conducted on 
nivolumab to assess its clinical effectiveness in real world settings. A strength of our meta-analysis 
was the use of the recently developed ‘meta-median’ package in R to obtain pooled summary 
estimates of median OS and PFS using study specific medians. Previously, these medians would be 
converted into means and standard errors for meta-analysis; however, the conversion assumed the 
outcome variables were normally distributed. Incorrect assumptions about the normality could 
introduce bias into meta-analyses using inverse variance weighting. McGrath and colleagues have 
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demonstrated that median-based meta-analyses performed better than conversion approaches 
(McGrath et al., 2020; McGrath et al., 2019).  
Our review had several limitations. First, the meta-analysis included aggregate data from published 
articles, and no individual patient data, which may have increased the level of statistical 
heterogeneity observed in the results. Heterogeneity may have also resulted from the different types 
of NSCLC evaluated in the included studies. Furthermore, the included articles did not uniformly 
report OS or PFS by strata of important potential effect modifiers such as age, smoking status, 
biomarker status, and ECOG-PS. Additionally, since PD-L1 level of expression is the only 
predictive biomarker for PD-1/PD-L1 inhibitors, we hoped to examine the association between PD-
L1 expression status and OS/PFS; however, the lack of data on PD-L1 levels in the included articles 
prevented us from carrying out this analysis. Thus, results of the meta-analyses should be 
interpreted with caution and considered to be solely exploratory in nature.  
3.6. Conclusion 
Our results suggest that real-world outcomes associated with nivolumab are consistent with what 
was observed in published RCTs. However, additional, large-scale, multicenter studies of high-





Chapter 4: Factors Affecting Treatment Selection and 
Overall Survival for First-Line EGFR-TKI Therapy in 
Non-Small-Cell Lung Cancer 
4.1. Abstract 
Aim: To investigate the factors associated with treatment selection and OS for first-line EGFR-
TKIs therapy among patients with non-small-cell lung cancer. Methods: We conducted a 
retrospective cohort study of linked administrative health databases in Ontario, Canada. Results: A 
total of 1,011 patients received an EGFR-TKI as first-line therapy. Treatment selection and OS 
associated with these treatments were affected by age, sex, geographical residency, comorbidities, 
and different sites of metastasis. Conclusion: Though recent approval of osimertinib offers a 
potential new standard of care in the first-line setting, earlier generation TKIs are still used to 
preserve osimertinib as a treatment option for later use. Our findings may contribute to optimizing 
treatment sequencing of upfront use of first- and second-generation use of EGFR-TKIs in the first-
line setting for the treatment of EGFR mutation-positive NSCLC. 
4.2. Introduction 
The epidemiology of lung cancer is specified in Chapter 2 of this thesis. Advancements in our 
understanding of cancer biology have allowed us to tailor treatment approaches based on patients’ 
genetic profiles. Half of NSCLC cases are associated with known mutations and several actionable 
gene alterations have been identified for targeted treatment (Dearden et al., 2013; Greulich, 2010; 
Korpanty, 2012). EGFR has been one of the most prevailing targets for devising specific treatment 
algorithms for patients with NSCLC. Approximately 15% of NSCLC cases have an activating 
mutation in the EGFR genes in exon 18-21 (Graham et al., 2018). Those harboring EGFR mutations 
are eligible to receive EGFR-TKIs, which have been demonstrated to improve ORR and PFS 
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compared to conventional chemotherapy in first-line settings (Fukuoka et al., 2011; Han et al., 
2012; Inoue et al., 2013; Maemondo et al., 2010; Mitsudomi et al., 2010; Rosell et al., 2012; Sequist 
et al., 2013; Wu et al., 2014; Wu et al., 2015; Yang et al., 2015; Yoshioka et al., 2019; Zhou et al., 
2011, Zhou et al., 2015).  
There are currently five EGFR-TKIs approved as first-line treatment for NSCLC in Canada, 
including the first-generation TKIs erlotinib (Tarceva; Hoffman-La Roche, Basel, Switzerland) and 
gefitinib (Iressa; AstraZeneca, London, UK), second-generation TKIs afatinib (Giotrif; Boehringer 
Ingelheim, Ingelheim, Germany) and dacomitinib (Vizimpro, Pfizer, New York, NY, USA), and 
third-generation TKI osimertinib (Tagrisso; AstraZeneca, London, UK). 
Currently, a dearth of clinical evidence exists to suggest whether one EGFR-TKI should be chosen 
over another among first- and second-generation EGFR-TKIs in a first-line setting (Girard, 2019; 
Nan et al., 2017). This suggests multiple factors could affect treatment selection, though a 
delineation of these factors in the case of EGFR-TKIs has never been undertaken. Previous research 
has identified general factors related to prescribing decisions, e.g., treatment sequencing, evidence 
from clinical trials, safety/toxicity profiles associated with each agent, growing familiarity with new 
agents among practitioners, regional/institutional preference, reimbursement, and influence of 
pharmaceutical companies (Fleischman et al., 2016; Schumock et al., 2004), though the 
applicability of these factors to EGFR-TKIs is unknown. 
While several randomized controlled trials (RCTs) and observational studies have estimated the 
efficacy/effectiveness of prognostic factor-guided EGFR-TKIs in advanced/metastatic EGFR 
mutation-positive NSCLC population (Chao, 2017; Fujiwara et al., 2018; Fukuoka et al., 2011; Han 
et al., 2012; Ho et al., 2019; Inoue et al., 2013; Ito et al., 2018; Li et al., 2019; Lin et al., 2019; 
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Maemondo et al., 2010; Mitsudomi et al., 2010; Perol et al., 2016; Rosell et al., 2012; Sequist et al., 
2013; Tokaca, 2018; Wu et al., 2014; Wu et al., 2015; Yang et al., 2015; Zhou et al., 2011, Zhou et 
al., 2015), limited information is available on the longitudinal effects of EGFR-TKIs at the 
population-level. Furthermore, evidence regarding the comparative effectiveness of these EGFR-
TKIs is inconsistent across the literature.  
To our knowledge, no studies thus far have investigated how prescribing decisions for EGFR-TKIs 
are made and the factors that may affect these prescribing decisions. Using population-based 
administrative health datasets, we sought to determine what factors influence the receipt of certain 
EGFR-TKIs in first-line settings and investigate how these are associated with overall survival. Due 
to the recency of the approval dates and concomitant lack of data for dacomitinib and osimertinib, 





4.3.1. Study Design 
This was a retrospective, population-based cohort study of linked health administrative data in 
Ontario, Canada. The datasets are housed at the Institute for Clinical Evaluative Sciences (ICES), a 
prescribed entity under Ontario’s Personal Health Information Protection Act. The Act authorizes 
ICES to draw individual patient-level data from multiple health administrative datasets for 
researchers to use in secondary analyses. The research was cleared for ethics by the Office of 
Research Ethics at the University of Waterloo (ORE # 41067). 
4.3.2. Study Population 
The study included all patients diagnosed with NSCLC in Ontario between January 1, 2010 and 
August 31, 2019. NSCLC cases were identified through the Ontario Cancer Registry (OCR). The 
International Classification of Diseases for Oncology, Third Edition (ICD-O-3) site codes 34.0-
34.9, in combination with relevant histology codes for non-squamous, squamous, and not otherwise 
specified (NOS) were used to identify cases of primary lung cancer from the OCR. Inclusion 
criteria were age ≥ 18 years at diagnosis, locally advanced or metastatic NSCLC, and receipt of 
afatinib, erlotinib, or gefitinib as first-line treatment. We excluded persons with death dates on or 
before the date of NSCLC diagnosis, and individuals who received more than one EGFR-TKI as 
first-line treatment. The dataset did not contain any information on biomarker status; thus, we 





4.3.3. Data Sources 
Multiple health administrative datasets were linked using encrypted unique identifiers. The OCR 
contains information on incident cancer cases and patients who have died of cancer in Ontario since 
1964 (Clarke et al., 1991; Robles et al., 1988). The OCR includes data on date and stage of NSCLC 
diagnosis, age, sex, geographical location, rural versus urban residence, and date of death. The 
Registered Persons Database (RPDB) contains demographic information and vital statistics on all 
residents of Ontario who are eligible for universal healthcare coverage in the province. The 
Canadian Institute for Health Information – Discharge Abstract Database (CIHI-DAD) contains 
data on diagnoses and procedures for all in- and outpatient hospital admissions. The Ontario Drug 
Benefits (ODB) database contains data on all prescription medications dispensed to those eligible 
for publicly funded drug coverage. These include all persons aged ≥65 years, persons living in 
homes for special care and long-term care homes, persons receiving professional services through 
the home and community care service programs, persons receiving social assistance, and persons 
receiving benefits through Trillium Drug Program, a scheme which help people with high 
prescription drug costs relative to their net household income. The ODB does not capture 
information covered by private insurance and compassionate supplies from manufacturers. The 
Activity Level Reporting (ALR) system contains information on systemic and radiation therapy 
services and outpatient oncology clinic visits. 
4.3.4. Covariates 
We searched the literature and consulted expert opinion to identify several sociodemographic and 
clinical factors that may influence treatment selection and OS (Bergqvist et al., 2020; Booth et al., 
2010; Charlson et al., 1987; Deyo et al., 1992; Girard, 2019; Hendriks et al., 2014; Kim et al., 2019;  
Lin et al., 2017; Schrijvers et al., 1997; Sorensen et al., 1988; Sperduto et al., 2017; Stavem et al., 
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2017). These factors included: year of diagnosis, age, sex, rurality. neighborhood income quintile, 
Local Health Integration Network (LHIN), clinical stage, histology, Charlson-Deyo Comorbidity 
Index (CCI), and sites of metastasis (bone, brain, liver, lung).   
Neighborhood household income was determined through linkage of postal codes to Canadian 
census data and stratified into three tertiles, with the first and last tertiles representing 
neighborhoods with the lowest and highest income status, respectively. CCI was determined from 
hospitalization data utilizing a two-year ‘look-back’ window, with the score from the most recently 
available hospitalization record applied to each participant (Charlson et al., 1987; Deyo et al., 
1992). We followed Stavem et al’s approach and considered missing comorbidities to be absent 
(Charlson et al., 1987; Deyo et al., 1992; Stavem et al., 2017). At the time of data collection, 
publicly funded healthcare services in Ontario were administered on a regional basis by 14 LHINs, 
each with its own distinct geographical territory. Recently, Ontario integrated these LHINS into five 
regions consisting of North, West, Toronto Central, East, and South regions. The analyses were 
conducted reflective of these changes. 
4.3.5. Statistical Analysis 
All variables were categorical and described using frequencies and percentages. To explore the 
factors associated with treatment selection, we conducted two separate logistic regression analyses 
comparing afatinib to gefitinib and erlotinib to gefitinib. We used gefitinib as the reference category 
because it was the most established treatment group among the three EGFR-TKIs; erlotinib and 
gefitinib have been in use since 2010, while afatinib was approved for use and publicly funded in 
2014. Furthermore, while erlotinib is only publicly funded for second- and third-line settings in 
Ontario, it is indicated for first line setting as well. The aim of our models was not to predict 
treatment selection, but to identify which variables may be of importance to clinicians prescribing 
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EGFR-TKIs for first-line treatment. Therefore, our focus was not to identify the most parsimonious 
model, but rather to build an explanatory model and examine the effects of all relevant covariates on 
treatment selection. 
A priori, we defined sociodemographic and clinical factors that may be important in clinical 
decision-making for treatment selection and its associated outcomes (see ‘Covariates’ above) 
(Bergqvist et al., 2020; Booth et al., 2010; Charlson et al., 1987; Deyo et al., 1992; Girard, 2019; 
Kim et al., 2019; Lin et al., 2017; Schrijvers et al., 1997). A series of chi-square tests were 
conducted to test the associations between independent variables and the outcome variable. In 
addition, all explanatory variables were checked for multicollinearity using variance inflation 
factors. Discrimination of the models was assessed with the area under the receiver operating 
characteristic curve (AUC). Calibration of the models was evaluated using the Hosmer Lemeshow 
goodness-of-fit tests.  
OS was assessed using the Kaplan-Meier method on the overall population and various patient 
subgroups. The OS was calculated from the date of diagnosis of NSCLC to death (for any reason) 
or the last day of patient follow-up (censored). Comparisons between groups were performed using 
the log rank test. Multivariable Cox proportional hazards models were used to determine adjusted 
hazard ratios (aHR) and to evaluate the predictive factors for survival. Statistical significance was 
set at 𝛼=0.05. All analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC). 
4.4. Results 
88,179 patients were identified as having a primary diagnosis of lung cancer in the OCR between 
2010 and 2019. Of these, 68,334 were NSCLC cases and 33,321 had stage IIIB/IV NSCLC. In total, 
1011 patients met the eligibility criteria and were enrolled in the study (  
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Table 5); 67 patients were excluded as they had records of receiving more than one EGFR-TKI in 
the first-line setting (Figure 8). 110 (10.9%) patients received afatinib, while 482 (47.7%) and 419 
(41.4%) received erlotinib and gefitinib, respectively. Male patients constituted 41.8% of the study 
population. Almost all patients had nonsquamous histology (98.7%) and no patients had squamous 
cell carcinoma. The majority of patients were at stage IV NSCLC (89.8%) at the time of diagnosis. 






Table 5 Table 1. Baseline patient sociodemographic and clinical characteristics 
 
Afatinib Erlotinib Gefitinib Total 
P-value 
n = 110 (%) n = 482 (%) n = 419 (%) n = 1011 (%) 
Year of Diagnosis  <.0001 
2010-2014 6 (5.4%) 425 (88.2%) 178 (42.5%) 609 (60.2%)  
2015-2019 104 (94.6%) 57 (11.8%) 241 (57.5%) 402 (39.8%)  
Age, years  <.0001 
18-59 36 (32.7%) 126 (26.1%) 84 (20.1%) 246 (24.3%)  
60-69 15 (13.6%) 85 (17.6%) 53 (12.7%) 153 (15.1%)  
70-79 55 (50.0%) 247 (51.3%) 217 (51.8%) 519 (51.3%)  
80+ 4 (3.6%) 24 (5.0%) 65 (15.5%) 93 (9.2%)  
Sex  <.0001 
Male 44 (40.0%) 245 (50.8%) 134 (32.0%) 423 (41.8%)  
Female 66 (60.0%) 237 (49.2%) 285 (68.0%) 588 (58.2%)  
Rurality  0.20 
Rural 15 (13.6%) 65 (13.5%) 41 (9.8%) 121 (12.0%)  




1 (poorest) 57 (51.8%) 208 (43.2%) 167 (39.9%) 432 (42.7%)  
2 16 (14.6%) 86 (17.8%) 78 (18.6%) 180 (17.8%)  





North 11 (10.3%) 30 (6.3%) 17 (4.1%) 58 (5.8%)  
West 27 (25.2%) 150 (31.4%) 84 (20.4%) 261 (26.2%)  
Toronto 9 (8.4%) 33 (6.9%) 55 (13.3%) 97 (9.7%)  
Central  34 (31.8%) 89 (18.6%) 168 (40.8%) 291 (29.2%)  
East 26 (24.3%) 176 (36.8%) 88 (21.4%) 290 (29.1%)  
Clinical Stage  0.06 
IIIB 11 (10.0%) 60 (12.4%) 32 (7.6%) 103 (10.2%)  
IV 99 (90.0%) 422 (87.6%) 387 (92.4%)  908 (89.8%)  
Histology  0.33 
Non-squamous 109 (99.1%) 478 (99.2%) 411 (98.1%) 998 (98.7%)  
Squamous Cell 0 (0%) 0 (0%) 0 (0%) 0 (0%)  
NOS 1 (0.9%) 4 (0.8%) 8 (1.9%) 13 (1.3%)  
Charlson Co-
morbidity Index (CCI) 
 0.25 
No 107 (97.3%) 452 (93.8%) 400 (95.5%) 959 (94.9%)  
Yes 3 (2.7%) 30 (6.2%) 19 (4.5%) 52 (5.1%)  
Sites of Metastasis   
Liver 16 (14.6%) 66 (13.7%) 44 (10.5%) 126 (12.5%) 0.27 
Bone 40 (36.4%) 150 (31.1%) 167 (39.9%) 357 (35.3%) 0.02 
Brain 26 (23.6%) 66 (13.7%) 98 (23.4%) 190 (18.8%) 0.0004 





4.4.1. Treatment Selection 
The results of the logistic regression analyses are presented in Table 6. We found no evidence of 
multicollinearity between explanatory variables. The goodness-of-fit of the models were confirmed 
(Hosmer-Lemeshow: Chi-square = 7.29 and p = 0.50 for gefitinib versus erlotinib; chi-square = 
8.33 and p = 0.40 for gefitinib versus afatinib) and the models exhibited moderate discriminatory 
capacity (AUC = 0.75 for gefitinib versus erlotinib; AUC = 0.69 for gefitinib versus afatinib). 
Age was associated with prescribing choice of EGFR-TKIs, with older patients more likely to be 
prescribed gefitinib over afatinib and erlotinib. Compared to patients aged 18-59 years, the adjusted 
odds ratio (aOR) for prescribing afatinib in lieu of gefitinib in patients aged ≥80 years was 0.14 
(95%CI: 0.04- 0.42), and 0.19 (95%CI: 0.10-0.34) for erlotinib versus gefitinib. A larger proportion 
of patients aged ≥70 years received gefitinib over the other two drugs. Erlotinib was more 
commonly prescribed for male patients compared to gefitinib (aOR: 2.59; 95%CI: 1.90-3.52). 
Regional prescribing preferences were evident. Patients residing in LHIN – North region, compared 
to Toronto Central, were less likely to be prescribed gefitinib over afatinib and erlotinib. The 
adjusted odds of receiving afatinib was 3.30 (95%CI: 1.02-10.64) times greater than receiving 
gefitinib, while it was 2.57 (95%CI: 1.15-5.75) times greater for erlotinib versus gefitinib. In the 
West and East regions, erlotinib was more commonly prescribed over afatinib and gefitinib. The 
adjusted odds of being prescribed erlotinib in the West region was 2.94 (95%CI: 1.68-5.14) and 
3.51 (95%CI: 2.01-6.11) in the East region.  
We found associations between sites of metastasis and prescribing decisions. Patients with 
metastasis to bone and brain were less likely to be prescribed erlotinib compared to gefitinib. 
Among patients with bone metastasis, the aOR for erlotinib prescription was 0.58 (95%CI: 0.42-
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0.80), while it was 0.53 (95%CI: 0.36-0.78) for patients with brain metastasis. However, erlotinib 
was more commonly prescribed for patients with liver metastasis compared to gefitinib, with an 
aOR of 1.74 (95%CI: 1.10- 2.78). 
Table 6 Adjusted odds ratios for prescription of afatinib and erlotinib compared to gefitinib 
Variable 






N= 110 482 419 
Age, years  
18-59 1 1 1 
60-69 0.83 (0.40-1.73) 1.12 (0.69-1.83) 1 
70-79 0.66 (0.39-1.12) 0.73 (0.50-1.06) 1 
80+ 0.14 (0.04-0.42) 0.19 (0.10-0.34) 1 
Sex  
Male 1.43 (0.89-2.27) 2.59 (1.90-3.52) 1 
Female 1 1 1 
Rurality  
Rural 1.10 (0.52-2.31) 0.98 (0.60-1.59) 1 




1 (poorest) 1.53 (0.78-2.97) 1.07 (0.71-1.63) 1 
2 1 1 1 
3 (wealthiest) 0.94 (0.47-1.87) 0.98 (0.64-1.48) 1 
LHIN  
North 3.30 (1.02-10.64) 2.57 (1.15-5.75) 1 
West 2.03 (0.86-4.82) 2.94 (1.68-5.14) 1 
Toronto 1 1 1 
Central 1.03 (0.45-2.34) 0.73 (0.42-1.26) 1 
East 1.66 (0.70-3.95) 3.51 (2.01-6.11) 1 
Clinical Stage  
IIIB 1.70 (0.75-3.85) 1.43 (0.84-2.44) 1 




No 1.58 (0.44-5.68) 0.81 (0.42-1.59) 1 
Yes 1 1 1 
Bone Metastasis  
Yes 0.78 (0.47-1.29) 0.58 (0.42-0.80) 1 










Liver Metastasis  
Yes 1.58 (0.78-3.20) 1.74 (1.10-2.78) 1 
No/Unknown 1 1 1 
Brain Metastasis  
Yes 1.14 (0.67-1.97) 0.53 (0.36-0.78) 1 
No/Unknown 1 1 1 
Lung Metastasis  
Yes 0.64 (0.36-1.16) 1.37 (0.96-1.95) 1 
No/Unknown 1 1 1 
CI – Confidence Interval; OR – Odds Ratio; LHIN – Local Health Integration Network;  
4.4.2. Survival Analysis 
The median OS of the overall cohort was 19.53 months (95%CI: 18.38-20.75) (Figure 9). 
Statistically significant differences in OS were observed across the EGFR-TKIs; the median OS 
were 31.04 months (95%CI: 23.41-42.05), 17.36 months (95%CI: 16.04-18.48), and 21.63 months 
(95%CI: 19.27-23.18) for afatinib, erlotinib, and gefitinib, respectively (Figure 10a). Significantly 
shorter OS was observed for patients who were male (median: 17.33 months, 95%CI: 16.01-18.97, 
p-value for log-rank test = 0.0017, Figure 10c), had presence of comorbidities (15.81 months, 
95%CI: 13.32-20.52, p-value for log-rank test = 0.026, Figure 10h), and had metastasis to liver 
(16.27 months, 95% CI: 14.14-18.44, p-value for log-rank test = 0.0001, Figure 10i) and bone 
(17.98 months, 95%CI: 16.21-20.38, p-value for log-rank test = 0.0094, Figure 10j). Furthermore, 











Figure 10 Overall survival by patient factors 
 
Overall survival according to treatment (afatinib, erlotinib, or gefitinib) (A); age groups (B); sex (C); income (D); 
geographical residency (E); rural vs. urban (F); clinical stage (G); presence of comorbidity (H); liver metastasis (I); 




A multivariable Cox regression model showed that prescription of erlotinib (aHR: 1.58, 95%CI: 
1.33-1.86, p< .0001), age 80+ (aHR: 1.42, 95%CI: 1.07-1.88, p=0.02), presence of comorbidities 
(aHR: 1.37, 95%CI: 1.01-1.86, p=0.04), liver metastasis (aHR: 1.49, 95%CI: 1.22-1.83, p=.0001), 
bone metastasis (aHR: 1.31, 95%CI: 1.13-1.53, p=0.0004), and brain metastasis (aHR: 1.30, 
95%CI: 1.07-1.57, p=0.007) were inversely associated with OS (Table 3). Prescription of afatinib 
(aHR: 0.61, 95%CI: 0.45-0.82, p=0.0013) was positively associated with OS (Table 7). 
Table 7 Multivariable Cox regression of overall survival 
Variable HR (95% CI) P-value 
EGFR-TKI 
Afatinib 0.61 (0.45-0.82) 0.0013 
Erlotinib 1.58 (1.33-1.86) <.0001 
Gefitinib Ref  
Age 
18-59 Ref  
60-69 0.86 (0.68-1.08) 0.18 
70-79 1.15 (0.96-1.37) 0.13 
80+ 1.42 (1.07-1.88) 0.02 
Sex  
Male 1.14 (0.99-1.32) 0.08 
Female Ref  
Rurality 
Urban Ref  
Rural 1.05 (0.84-1.30) 0.67 
Clinical Stage 
IIIB 1.05 (0.83-1.34) 0.68 
IV Ref  
Charlson Co-morbidity Index 
No Ref  
Yes 1.37 (1.01-1.86) 0.04 
Income 
Poorest Ref  
Middle 1.09 (0.90-1.32) 0.40 
Wealthiest 1.04 (0.89-1.21) 0.67 
LHIN 
North 1.35 (0.92-1.97) 0.12 
West 1.13 (0.86-1.48) 0.40 
Toronto Ref  
Central 1.05 (0.81-1.37) 0.72 
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Variable HR (95% CI) P-value 
East 1.15 (0.88-1.50) 0.30 
Liver Metastasis 
No Ref  
Yes 1.49 (1.22-1.83) 0.0001 
Bone Metastasis 
No Ref  
Yes 1.31 (1.13-1.53) 0.0004 
Brain Metastasis 
No Ref  
Yes 1.30 (1.07-1.57) 0.007 
Lung Metastasis 
No Ref  
Yes 0.94 (0.80-1.11) 0.48 
HR – Hazards Ratio; CI – Confidence Interval; LHIN – Local Health Integration Network; Ref – Reference 
4.5. Discussion 
We identified sociodemographic and clinical factors influencing treatment selection and OS among 
patients who received EGFR-TKIs between 2010-2019. Compared to gefitinib, erlotinib was 
prescribed more frequently for those who were males, residing in certain geographical locations 
(North, West, and East regions), and had liver metastasis. The results for afatinib were similar, 
while a higher prescription of afatinib was noted among patients with no comorbidities and who had 
brain metastasis, although the results were not statistically significant. Compared with afatinib and 
erlotinib, gefitinib was more commonly prescribed for older patients and those with bone 
metastasis. Meanwhile, it was found that type of EGFR-TKI therapy, age, presence of 
comorbidities, and metastasis to liver, bone, and brain could be independent prognostic factors for 
OS.  
We expected to find some of the associations reported in Tables 2 and 3. In terms of the use of 
gefitinib for patients with bone metastasis, previous studies suggested that gefitinib may reduce 
bone metastasis growth through inhibition of EGF signaling pathways in bone stromal cells and 
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improve pathologic fractures (Lu et al., 2009; Okano & Nishio, 2008). Furthermore, the high usage 
of gefitinib in older patients may partly be explained by the safety/toxicity profile of afatinib 
compared to erlotinib or gefitinib. While results from the noninterventional RealGiDo study 
indicated that AEs with afatinib can be managed with dose adjustments and care measures (Halmos 
et al., 2019), older patients may not be able to handle the intensity of AEs associated with afatinib. 
For patients with terminal NSCLC, the intent of treatment would likely focus on health-related 
quality of life, which involves minimizing treatment related AEs and managing symptoms. 
Another factor to consider is acquired resistance, the most common being the development of a 
T790M mutation, which occurs in 50%-70% of cases (Arcila et al., 2011; Sequist et al., 2011; Yang 
et al., 2017). Studies have shown that afatinib is able to overcome acquired first-generation EGFR-
TKI resistance (Heigener & Reck, 2011; Heigener et al., 2015). While afatinib is not publicly 
funded for second-line settings in Ontario, funding of afatinib for patients who have initiated 
another EGFR-TKI therapy in the first line setting, and who have not had disease progression, are 
considered on a case-by-case basis. 
Our median OS estimate stratified by EGFR-TKIs are inconsistent with what has been reported in 
several trials (Fukuoka et al., 2011; Han et al., 2012; Inoue et al., 2013; Maemondo et al., 2010; 
Mitsudomi et al., 2010; Rosell et al., 2012; Sequist et al., 2013; Wu et al., 2015; Yang et al., 2015; 
Yoshioka et al., 2019; Zhou et al., 2011, Zhou et al., 2015). The median OS observed in our study 
for erlotinib and gefitinib were shorter than what was observed in most published trials. Exception 
was the results reported in the IPASS trial, where median OS was 18.8 months for gefitinib 
(Fukuoka et al., 2011). However, the median OS of afatinib observed in our study was longer than 
what was reported in phase IIb LUX-Lung 7 trial (27.9 months) and phase III LUX-Lung 3 (28.2 
months) and LUX-Lung 6 (23.1 months) trials (Han et al., 2012; Park et al., 2016; Yang et al., 
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2015). The differences in median OS between EGFR-TKIs was consistent with other observational 
studies that reported effectiveness of EGFR-TKIs in clinical practice (Bergqvist et al., 2020; Chao, 
2017; Clarke et al., 1991; Fujiwara et al., 2018; Ho et al., 2019; Ito et al., 2018; Li et al., 2019; Lin 
et al., 2019; Perol et al., 2016; Robles et al., 1988; Tokaca, 2018). Most studies reported higher 
median OS associated with afatinib compared to erlotinib or gefitinib (Fujiwara et al., 2018; Ito et 
al., 2018; Lin et al., 2019). However, Li and colleagues reported higher median OS observed in 
patients receiving erlotinib (23.2 months) compared to afatinib (20.7 months) (Lin et al., 2019). In 
addition, Chao and colleagues reported substantially higher median OS for patients receiving 
erlotinib (34.6 months) compared to those receiving gefitinib (19.2 months) (Chao, 2017). 
Given the fact that 15% of patients with non-squamous histology whose tumor harbor EGFR 
mutation, we had expected a larger sample for our study. However, the relatively small sample size 
could be attributed to the initial challenges of implementing biomarker testing in Ontario in the 
early 2010s, along with logistical difficulties, e.g., delayed turnaround times, which led 
chemotherapy to be used as the first-line treatment to avoid clinical deterioration (Cheema et al., 
2017; Ellis et al., 2013). A previous study has suggested that approximately 1 in 4 patients do not 
undergo biomarker testing (Spicer, 2015). Furthermore, the ODB database captured only 
information related to publicly funded medications; therefore, prescription medications covered by 
private insurance and compassionate supplies from manufacturers could not be considered. 
We found that 38.9% of our study cohort initiated a second line therapy, which questions the notion 
of reserving therapies for subsequent use (e.g. development of acquired T790M mutation resistance) 
to maximize the duration of chemotherapy-free treatment. The results from the phase III FLAURA 
trial demonstrated superior efficacy and safety profiles associated with osimertinib compared to 
first-generation TKIs in the first-line setting, regardless of T790M mutational status (Soria et al., 
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2018). In terms of treatment sequencing, patients receiving osimertinib as first-line treatment would 
not receive any subsequent EGFR-TKIs upon progression and would likely involve treatment with 
platinum doublet. Therefore, clinical challenges remain in deciding whether the most effective 
therapy should be used as first-line treatment or be reserved for later lines to expand treatment 
options. 
A strength of our study was the linkage and use of population-based administrative datasets, which 
captured all relevant data and complete follow-up for all patients. To our knowledge, this was the 
first study to systematically assess the factors influencing prescribing decisions associated with 
EGFR-TKIs using administrative datasets.  
Nonetheless, our study has limitations. First, the number of patients who received afatinib was 
relatively small compared to patients who received erlotinib and gefitinib, due to later approval of 
afatinib. The difference in sample size resulting from the late licensing date may have contributed to 
selection and length-time bias in our study, which may have caused overestimation of odds ratios 
and survival estimates in our analyses. The overall survival data for persons who received erlotinib 
and gefitinib were more mature compared to persons who received afatinib. In addition, previous 
studies have demonstrated the importance of ECOG-PS and the type of EGFR mutation status, e.g., 
exon 19 deletion (Exon19DEL) and the exon 21 codon 858 point mutation (L858R), as important 
factors to consider in treatment selection and survival (Cha et al., 2015; Hung et al., 2018; Jackman 
et al., 2006; Pirker et al., 2012; Ren et al., 2014; Riely et al., 2006; Tu et al., 2017; Yang et al., 
2015). However, a lack of data on ECOG-PS and EGFR mutation status prohibited us from carrying 
out any analyses involving these factors. We assumed that patients who received any of the three 
EGFR-TKI had positive EGFR mutation, regardless of the type. Although highly unlikely, we 
cannot rule out the possibility that TKIs may have been prescribed to EGFR wild-type patients. 
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Lastly, since the ODB database did not capture information on private insurance claims and 
compassionate supplies, we were not able to assess prescribing differences based on types of 
insurance. 
4.6. Conclusion 
The results of the present study demonstrated that factors such as age, sex, geographical residency, 
and metastasis to bone, liver, and brain were independent factors influencing treatment selection of 
EGFR-TKIs. Presence of comorbidities, in addition to the aforementioned factors, were 
independent prognostic factors for OS. In clinical practice, there were significant differences in 
overall survival between the three EGFR-TKIs. Additional population-based studies are required to 






Chapter 5: Cost-Effectiveness Analysis of Afatinib, 
Erlotinib, and Gefitinib as First-Line Treatment for 
EGFR Mutation-Positive Non-Small-Cell Lung 
Cancer in Ontario, Canada 
5.1. Abstract 
Objective: The objective of this study was to compare the cost effectiveness of first-line 
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for the treatment of 
non-small-cell lung cancer. Methods: This study used Ontario Cancer Registry-linked 
administrative data to identify patients with a primary diagnosis of lung cancer who received 
EGFR-TKIs as first-line treatment between 1 January, 2014 and 31 August, 2019. A net benefit 
regression approach accounting for baseline covariates and propensity scores was used to 
estimate incremental net benefits and incremental cost-effectiveness ratios. Outcome measures 
were calculated over a 68-month period and were discounted with an annual rate of 1.5%. 
Sensitivity analyses were conducted to assess and characterize the uncertainties. Results: A total 
of 547 patients were included in the study, of whom 20.1%, 23.6%, and 56.3% received afatinib, 
erlotinib, and gefitinib, respectively. Erlotinib was dominated by afatinib and gefitinib. 
Compared to gefitinib, afatinib was associated with higher effectiveness (adjusted incremental 
quality-adjusted life-year: 0.21), higher total costs (adjusted incremental costs: $9745), and an 
incremental cost-effectiveness ratio of $46,506 per quality-adjusted life-year gained. Results 
from the sensitivity analyses indicated the findings of the base-case analysis were robust. 
Conclusions: Contrary to previously published studies, our study established head-to-head 
comparisons of effectiveness and treatment-related costs of first-line EGFR-TKIs. Our findings 




The epidemiology of lung cancer is specified in Chapter 2 of this thesis. Roughly half of all 
NSCLC cases are associated with known genetic mutations, 15% of which are linked to an 
activating mutation in the EGFR genes (Graham et al., 2018). TKIs of the EGFR have become 
the standard treatment for patients with advanced NSCLC harboring an EGFR mutation. 
Compared to conventional chemotherapy, EGFR-TKIs have shown improved ORR and PFS in 
first-line settings (Fukuoka et al., 2011; Han et al., 2012; Inoue et al., 2013; Maemondo et al., 
2010; Mitsudomi et al., 2010; Rosell et al., 2012; Sequist et al., 2013; Wu et al., 2014; Wu et al., 
2015; Yang et al., 2015; Yoshioka et al., 2019; Zhou et al., 2011, Zhou et al., 2015). 
Recent approval of osimertinib offers a potential new standard of care in the first line setting for 
treatment of advanced or metastatic EGFR mutation-positive NSCLC (Mok et al., 2017; Soria et 
al., 2018). However, two popular treatment protocols for EGFR-TKIs currently exist; one 
involves front-line use of osimertinib, while the other involves front-line use of first- or second-
generation EGFR-TKIs, followed by osimertinib as second-line salvage therapy for patients who 
progress and develop resistance through the T790M mutation (Girard, 2019). There is no 
concrete evidence to suggest one treatment protocol is superior to another, indicating earlier 
generation EGFR-TKIs (i.e., afatinib, erlotinib, and gefitinib) remain a mainstay of first-line 
treatment options in clinical practice.  
Previous studies that compared the effectiveness and cost-effectiveness of first-line EGFR-TKIs 
generally used model-based analyses whereby parameterization of model inputs and assumptions 
were largely derived from randomized controlled trials (RCTs) (Arrieta et al., 2020; Chouaid et 
al., 2017; Gu et al., 2019; Lee et al., 2014; Ting et al., 2015; Yang et al., 2020). The use of model 
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analyses is associated with many limitations such as incorporation of model assumptions (e.g., 
Markovian assumption), restrictive inclusion and exclusion criteria, limited lengths of follow-up, 
extrapolation of observed survival data, and limited information on treatment-related healthcare 
costs. Furthermore, previous studies have used conventional chemotherapy as the comparator to 
infer effectiveness through indirect treatment comparisons across EGFR-TKIs (Gu et al., 2019; 
Ting et al., 2015). Hence, the use of real-world data to directly compare the effectiveness and 
cost-effectiveness of EGFR-TKIs may help inform or revise healthcare resource allocation 
decisions.  
The aim of our study was to assess the comparative cost-effectiveness of three EGFR-TKIs – 
afatinib, erlotinib, and gefitinib – for first-line treatment of advanced and metastatic NSCLC 
using a large, population-based, person-level claims database from a healthcare payer 
perspective. The present study was limited to these three EGFR-TKIs due to the lack of real-
world data and recent regulatory approval for dacomitinib and osimertinib.  
5.3. Methods 
5.3.1. Study Design 
This was a retrospective cohort study of linked health administrative data in the province of 
Ontario, Canada. The datasets are housed at the ICES, a prescribed entity under Ontario’s 
Personal Health Information Protection Act. The Act authorizes ICES to draw individual patient-
level data from multiple health administrative datasets for researchers to use in secondary 
analyses. Our research was cleared for ethics by the Office of Research Ethics at the University 




5.3.2. Study Population 
The study included all eligible NSCLC cases in Ontario between January 01, 2014 and August 
31, 2019. The dates were chosen in alignment with the year afatinib became commercially 
available in Ontario to latest available data at time of analysis (gefitinib and erlotinib were 
available prior to 2014). We identified cases of primary lung cancer using the ICD-O-3 site 
codes 34.0-34.9, in combination with relevant histology codes for non-squamous, squamous, and 
not otherwise specified. Inclusion criteria were age ≥18 years at diagnosis, locally advanced or 
metastatic NSCLC, and records of receipt of afatinib, erlotinib, or gefitinib as first-line 
treatment. Persons with recorded death dates on or before the date of NSCLC diagnosis, and 
persons who had records of receipt of ≥1 EGFR-TKI in first-line settings were excluded from the 
study. Information on biomarker status was not available in the dataset and we therefore assumed 
patients with records of EGFR-TKI prescription in first-line settings had positive EGFR mutation 
status.   
5.3.3. Data Sources 
We linked multiple health administrative datasets using encrypted unique identifiers. NSCLC 
cases were identified through the OCR, which contains information on incident cancer cases and 
patients who have died of cancer in Ontario since 1964 (Clarke et al., 1991; Robles et al., 1988). 
The OCR includes data on date of diagnosis, stage of NSCLC at incident diagnosis, age, sex, 
geographical location, residency (rural versus urban), and date of death, among others. The 
RPDB contains demographic information and vital statistics on all residents of Ontario who are 
eligible for universal healthcare coverage in the province. The CIHI-DAD holds data on 
diagnoses and procedures for all in- and outpatient hospital admissions. The ODB database 
contains data on all prescription medications dispensed to persons eligible for publicly-funded 
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drug coverage, including those aged ≥65 years, living in homes for special care and long-term 
care homes, receiving professional services through the home or community care service 
programs, receiving social assistance, and receiving benefits through the Trillium Drug Program, 
a scheme which provides assistance for people with high prescription drug costs relative to their 
net household income. The ODB does not capture information covered by private insurance or 
compassionate use programs from manufacturers. The ALR system contains information on 
systemic and radiation therapy services and outpatient oncology clinic visits provided to persons 
diagnosed with cancer. The NDFP database contains information on indication for use of all 
publicly funded intravenous drug therapies administered in -hospital and -cancer clinics in 
Ontario. The NDFP is a publicly funded drug program in Ontario that covers the costs of many 
novel and expensive intravenous cancer therapies. 
5.3.4. Covariates 
We identified several sociodemographic and clinical factors that may influence treatment 
selection and outcomes (overall survival [OS] and costs) through the literature and inputs derived 
from consultation with an expert (Bergqvist et al., 2020; Booth et al., 2010; Charlson et al., 1987; 
Deyo et al., 1992; Girard, 2019; Kim et al., 2019; Lin et al., 2017; Schrijvers et al., 1997). These 
factors included year of diagnosis, age, sex, residency, neighborhood income quintile, 
geographical residency within the province (i.e., North, West, Toronto, Central, East), clinical 
stage, histology, CCI, and sites of metastasis (e.g., bone, brain, liver, lung).  
Neighborhood household income was determined through linkage of postal codes to Canadian 
census data and was stratified into three tertiles, with the first and last tertiles representing 
neighborhoods with the lowest and highest income status, respectively. CCI was determined 
from hospitalization data using a two-year ‘look-back’ window and the scores were retrieved 
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from the most recent hospitalization record for each person. We followed Stavem et al.’s 
approach and considered missing comorbidities to be absent (Stavem et al., 2017). At the time of 
data collection, publicly funded healthcare services in Ontario were administered on a regional 
basis by 14 LHINs, each with its own distinct geographical territory. Recently, these LHINS 
were integrated into five regions consisting of North, West, Toronto Central, East, and South 
regions. We identified geographical residency based on these regions. 
5.3.5. Outcomes 
We conducted our cost-effectiveness analyses using life-year (LY) gained and quality-adjusted 
life-year (QALY) gained as our measures of effectiveness. LY was measured as OS using the 
Kaplan-Meier method to estimate the mean OS. The OS was calculated from the date of 
diagnosis of NSCLC to death (for any reason) or the last day of follow-up (censored). QALY 
was calculated as the product of the utility score and the mean OS. Due to a lack of available 
data on progression, a single utility value of 0.75 was used to estimate the QALYs (Jiang et al., 
2019; Labbe et al., 2017). The analysis was conducted over a 68-month study period. 
5.3.6. Costs 
The present study only considered direct healthcare costs in accordance with the payer’s 
perspective. Individual-level healthcare costs were computed using a macro-based costing 
methodology ‘GETCOST’, which is available at ICES (Wodchis, Bushmeneva, Nikitovic, & 
McKillop, 2013). The healthcare services that we costed in this study included in-patient 
hospitalization, out-patient clinic visits, same-day surgeries, emergency department (ED) visits, 
cancer clinic visits, prescription drugs, rehabilitation services, complex continuing care (CCC), 
long-term care (LTC), home care (HC), physician services, laboratory, mental health (MH) 
admissions, assistive devices, and NDFP.  
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Cost estimates for same-day surgeries and ED visits were obtained from the National 
Ambulatory Care Reporting System (NACRS) database. Cost estimates for hospitalization, 
same-day surgeries, and ED visits were estimated using the Resource Intensity Weight (RIW) 
methodology developed by CIHI (Jacobs, 2009). Costs associated with physician visits and 
laboratory tests were estimated from the physicians claims history in the Ontario Health 
Insurance Plan (OHIP) claims database. Costs associated with HC, LTC, and CCC were 
estimated from the HC, Continuing Care Reporting System (CCRS), and ODB databases. Costs 
of prescription drugs were obtained from the ODB database, while costs of NDFP drugs were 
measured per actual dose and estimated from the NDFP database. Costs associated with MH 
admissions were obtained from the Ontario Mental Health Reporting System (OMHRS).  
All costs were adjusted for inflation to 2020 Canadian dollars using the Statistics Canada 
Consumer Price Index for health care and personal items for Ontario (Statistics Canada). 
Effectiveness and cost data were discounted at an annual rate of 1.5% (CADTH, 2017).  
5.3.7. Statistical Analysis 
A net benefits regression (NBR) framework was used to assess the comparative cost-
effectiveness of afatinib, erlotinib, and gefitinib (Hoch & Dewa, 2008). We estimated the net 
benefit value for the ith person using the following formula: NB = λEi – Ci, where λ represented 
the pre-determined willingness-to-pay (WTP) threshold value, Ei represented the observed effect 
and Ci represented costs, for the ith person. Various ranges of λ values were explored in our 
analyses, ranging from $0 to $200,000 (Raymaykers et al., 2020). The general rule associated 
with NBR frameworks is to assume new interventions are cost-effective if INB >0 at a specified 
threshold λ.  
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NBR involved fitting a linear regression model adjusting for relevant covariates to the outcome 
(see Covariates above). Three separate regression models were constructed for afatinib versus 
gefitinib, afatinib versus erlotinib, and gefitinib versus erlotinib. We adjusted for propensity 
scores to minimize bias for non-random allocation of samples to EGFR-TKI treatment; 
propensity scores were included in the linear regression models to calculate INBs to generate 
ICERs and uncertainty measures. A propensity score is each participant’s probability of being 
assigned to the exposed/treatment group given a set of observed individual covariates (Austin, 
2011). We calculated the propensity scores using logistic regression models with EGFR-TKI 
treatment as the dependent variable and the covariates described above as independent variables.  
Censored observations were taken into account by using inverse probability of censoring weights 
(IPCW). Logistic regression was used to calculate the probability of being censored for each 
individual based on treatment and observed individual covariates. Individuals were weighted by 
the inverse of their predicted probability of not being censored. All independent variables 
included in the model were evaluated for multicollinearity prior to inclusion.  
In its simplest form, NBR involves fitting a linear regression model with an equation:  
NBi = β0 + β1TXi + εi  
Where NBi is the person-level NB; β0 is an intercept term; TXi is the treatment indicator (i.e., 
TXi = 1 for new treatment and 0 for usual care) and εi is the stochastic error term. The dependent 
variable NBi is modelled as a function of relevant covariates and the error term. The regression 
coefficient β1 provides the estimate of the incremental net benefit (INB) of new intervention 
versus the usual care accounting for λ.      
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Our final NBR model was as follows: 
NBi = β0 + β1(EGFR-TKI)i + β2(age)i + β3(sex)i + β4(year of diagnosis)i + β5(rural versus urban)i 
+ β6(neighborhood income)i + β7(geographical residency)i + β8(clinical stage)i + 
β9(comorbidities)i + β10(liver metastasis)i + β11(bone metastasis)i + β12(brain metastasis)i + 
β13(lung metastasis)i + β14(propensity score)i + εi         
IPCW were applied to the model to account for differential censoring. Statistical significance 
was set at 𝛼=0.05. All analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, 
NC) and STATA version 12.0 (Stata Corporation, College Station, TX). 
5.3.8. Sensitivity Analysis 
To characterize the uncertainties associated with INB estimates, three sensitivity analyses were 
conducted. First, a one-way deterministic sensitivity analysis was conducted to examine the 
impact of varying utility scores on the ICER by using the lower and upper bounds of the health 
state utilities (±0.04). Second, the INB and its 95% CI were plotted against various ranges of λ 
values. Third, we used non-parametric bootstrapping to draw 1,000 samples of INB estimates 
and constructed cost-effectiveness acceptability curves (CEACs). A CEAC displays the 
probability that an intervention is cost-effective compared to its alternative under ranges of λ 
values.     
5.4. Results 
A total of 547 patients met the eligibility criteria and were included in the study (Table 8). Of 
these, 110 (20.1%) received afatinib, while 129 (23.6%) and 308 (56.3%) patients received 
erlotinib and gefitinib, respectively. Over half of the study sample (51.9%) were aged 70 to 79 
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years and 39.3% were males. Almost all patients (98.7%) had non-squamous histology and had 
stage IV NSCLC (91.4%) at time of diagnosis.  
Table 8 Baseline Characteristics of the Study Population 
 
Afatinib Erlotinib Gefitinib Total 
n = 110 (%) n = 129 (%) n = 308 (%) n = 547 (%) 
Year of Diagnosis  
2014-2016 52 (47.3%) 125 (96.9%) 205 (66.6%) 382 (69.8%) 
2017-2019 58 (52.7%) 4 (3.1%) 103 (33.4%) 165 (30.2%) 
Age, years  
18-59 36 (32.7%) 25 (19.4%) 62 (20.1%) 123 (22.5%) 
60-69 15 (13.6%) 24 (18.6%) 32 (10.4%) 71 (13.0%) 
70-79 55 (50.0%) 70 (54.3%) 159 (51.6%) 284 (51.9%) 
80+ 4 (3.7%) 10 (7.7%) 55 (17.9%) 69 (12.6%) 
Sex  
Male 44 (40.0%) 71 (55.0%) 100 (32.5%) 215 (39.3%) 
Female 66 (60.0%) 58 (45.0%) 208 (67.5%) 332 (60.7%) 
Rurality  
Rural 15 (13.6%) 17 (13.2%) 28 (9.1%) 60 (11.0%) 




1 (poorest) 57 (51.8%) 63 (48.8%) 127 (41.2%) 247 (45.2%) 
2 16 (14.6%) 25 (19.4%) 55 (17.9%) 96 (17.5%) 
3 (wealthiest) 37 (33.6%) 41 (31.8%) 126 (40.9%) 204 (37.3%) 
Geographical Residency  
North 11 (10.3%) 9 (7.0%) 10 (3.3%) 30 (5.5%) 
West 27 (25.2%) 38 (29.5%) 62 (20.3%) 127 (23.5%) 
Toronto 9 (8.4%) 8 (6.2%) 42 (13.8%) 59 (10.9%) 
Central  34 (31.8%) 30 (23.2%) 126 (41.3%) 190 (35.1%) 
East 26 (24.3%) 44 (34.1%) 65 (21.3%) 135 (25.0%) 
Clinical Stage  
IIIB 11 (10.0%) 13 (10.1%) 23 (7.5%) 47 (8.6%) 
IV 99 (90.0%) 116 (89.9%) 285 (92.5%) 500 (91.4%) 
Histology  
Non-squamous 109 (99.1%) 127 (98.5%) 304 (98.7%) 540 (98.7%) 
Squamous Cell 0 0 0 0 
NOS 1 (0.9%) 2 (1.5%) 4 (1.3%) 7 (1.3%) 
CCI  
No 107 (97.3%) 119 (92.2%) 295 (95.8%) 521 (95.2%) 
Yes 3 (2.7%) 10 (7.8%) 13 (4.2%) 26 (4.8%) 
Site of Metastasis  
Liver 16 (14.6%) 25 (19.4%) 31 (10.1%) 72 (13.2%) 
Bone 40 (36.4%) 38 (29.5%) 121 (39.3%) 199 (36.4%) 
Brain 26 (23.6%) 18 (14.0%) 69 (22.4%) 113 (20.7%) 
Lung 19 (17.3%) 30 (23.3%) 68 (22.1%) 117 (1.4%) 




Effectiveness and incurred costs were stratified according to each treatment and are summarized 
in Table 9. Highest survival was observed among persons who received afatinib as first-line 
treatment (mean LY: 2.67, standard error [SE]: 0.16), followed by persons who received 
gefitinib (mean LY: 2.23, SE: 0.10) and erlotinib (mean LY: 1.68, SE: 0.10). Furthermore, 
afatinib was associated with the lowest costs (mean costs: $130,717), followed by gefitinib 
(mean costs: $137,037) (Table 10).  
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CI: Confidence Interval; LY: Life Year; QALY: Quality-Adjusted Life Year; SD; Standard Deviation; SE: Standard 
Error 
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5.4.2. Net benefit regression 
Incremental effectiveness (LY and QALY) and costs are summarized in Table 11. In the adjusted 
model, erlotinib was dominated by both afatinib and gefitinib, indicating erlotinib as the least 
cost-effective option among the three treatments. Compared to gefitinib, afatinib demonstrated 
higher effectiveness (incremental LY: 0.28, incremental QALY: 0.21) with higher incremental 
costs ($9,745). The ICER estimate for afatinib compared to gefitinib was $34,879 per LY gained 
or $46,506 per QALY gained. 
Table 11 Adjusted Incremental Effectiveness, Incremental Costs, and Incremental Cost-

























0.28 0.21 $9,745 $34,879 $46,506 
Gefitinib vs. 
Erlotinib 





ICER: Incremental Cost-Effectiveness Ratio; LY: Life Year; QALY: Quality-Adjusted Life Year 
The NB estimates for QALYs are summarized in Table 12 and Table 13 (Appendix G and 
Appendix H for LYs). Afatinib was not cost-effective compared to gefitinib at WTP values 
ranging between $0 and $40,000/QALY gained. Beyond the WTP value of $46,506, afatinib was 
cost-effective over gefitinib. Year of diagnosis significantly increased NB at WTP values 
between $0 and 50,000/QALY gained. Metastasis to bone and brain significantly reduced NB at 
WTP values between $0-$50,000, and $0-$100,000/QALY gained, respectively. Age group 
significantly reduced NB at WTP values between $50,000 and $100,000/QALY gained, while 
female sex significantly increased NB at WTP values between $50,000 and $100,000/QALY 
gained. (Table 12). 
 
76 
Table 12 Net Benefit Estimates for Afatinib versus Gefitinib – QALY 
Covariates NB  
(95% CI) 
Net Benefits λ = 0 Net Benefits λ = 20000 Net Benefits λ = 50000 Net Benefits λ = 100000 




























































































































































































0.0011 0.4274 0.0003 0.3979 0.0028 0.3053 0.0043 0.1079 





Table 13 Estimates of Incremental Net Benefit and Probability of Cost-Effectiveness of Afatinib, Erlotinib, and Gefitinib - 
QALY. 


















$0 -9745 (6350) 0.126 0.022 1549 (10948) 0.888 0.703 13610 (9458) 0.151 0.919 
$10,000 -7650 (7579) 0.209 0.038 6811 (10328) 0.510 0.854 15511 (9070) 0.088 0.978 
$20,000 -5554 (5855) 0.343 0.069 12074 (9792) 0.219 0.955 17411 (8750) 0.047 0.996 
$30,000 -3459 (5700) 0.544 0.112 17337 (9353) 0.065 0.996 19312 (8506) 0.024 0.999 
$40,000 -1363 (5616) 0.808 0.209 22600 (9025) 0.013 1.000 21213 (8345) 0.011 1.000 
$50,000 732 (5604) 0.896 0.350 27862 (8822) 0.002 1.000 23113 (8271) 0.005 1.000 
$60,000 2828 (5666) 0.618 0.518 33125 (8751) <.001 1.000 25014 (8286) 0.003 1.000 
$70,000 4923 (5799) 0.396 0.653 38388 (8817) <.001 1.000 26915 (8391) 0.001 1.000 
$80,000 7019 (5999) 0.243 0.752 43650 (9015) <.001 1.000 28816 (8581) 0.001 1.000 
$90,000 9114 (6258) 0.146 0.843 48913 (9338) <.001 1.000 30716 (8852) 0.001 1.000 
$100,000 11210 (6570) 0.089 0.893 54176 (9773) <.001 1.000 32617 (9196) <.001 1.000 
$150,000 21687 (8695) 0.013 0.984 80489 (13148) <.001 1.000 42121 (11745) <.001 1.000 





5.4.3. Sensitivity Analysis 
Results from the one-way deterministic sensitivity analysis suggested the findings of the base-
case analysis were robust. Erlotinib was dominated by both afatinib and gefitinib, while afatinib 
remained appear to be cost-effective over gefitinib under the WTP threshold of $50,000 per 
QALY gained, with ICERs of $49,126 and $44,151 per QALY gained for lower and upper 
bounds of health state utilities, respectively. 
Figure 11 (Appendix I for LYs) depict INB estimates and its 95% CIs by range of WTP values. 
The ICER estimate can be visually seen on the graph where the INB estimate equals to zero on 
the x-axis. The 95%CI of the INB estimate suggest there is uncertainty of cost-effectiveness of 
afatinib at a WTP value of $46,506 (ICER) per QALY gained. However, at a WTP value of 
approximately $110,00 per QALY gained and beyond, afatinib is significantly cost-effective as 
indicated by the INB estimates and its confidence intervals >0.  
Figure 12 (Appendix J for LYs) depict the probability of cost-effectiveness of afatinib over 
gefitinib as a function of WTP threshold for additional QALY. The results showed that at the 
commonly cited WTP value of $50,000/QALY gained, afatinib had 35.0% probability of being 
cost-effective. At the WTP value of $100,000/QALY gained, afatinib had 89.3% probability of 




Figure 11 Incremental Net Benefit by Willingness-To-Pay for Afatinib versus Gefitinib - 
QALY 
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Figure 12 Cost Effectiveness Acceptability Curve for Afatinib versus Gefitinib - QALY 
 
QALY: Quality-Adjusted Life Year 
 
5.5. Discussion 
The present study assessed the comparative cost-effectiveness of three first-line EGFR-TKIs for 
treatment of NSCLC. The results of our analysis suggest erlotinib as the least cost-effective 
option and afatinib as the most cost-effective treatment under the commonly cited 
$50,000/QALY gained WTP threshold. Though afatinib demonstrated higher effectiveness 
(incremental QALY: 0.21) compared to gefitinib, the additional benefits were associated with 
higher costs (incremental cost: $9,745), which resulted in an ICER estimate of $46,506 per 
QALY gained. This notion was also ascertained as shown in the CEAC where afatinib had 
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Most cost-effectiveness analyses conducted for first-line EGFR-TKIs were assessed using 
information inferred from RCTs. Due to a lack of head-to-head data, previous studies measured 
effectiveness through indirect treatment comparisons from distinct RCTs. Lee et al. assessed the 
cost-effectiveness of erlotinib versus gefitinib and found an ICER estimate of $62,419 per 
QALY gained; however, the effectiveness was estimated through indirect comparison using 
OPTIMAL and IPASS trials (Lee et al., 2014). Similarly, Ting et al. calculated an ICER estimate 
of $61,809 per QALY gained for erlotinib versus gefitinib through indirect comparison (Ting et 
al., 2015), while Chouaid et al. calculated an ICER estimate of €45,211 per QALY gained for 
afatinib versus gefitinib using a head-to-head data from LUX-Lung 7 trial (Chouaid et al., 2017). 
Recently, Yang et al. directly compared the cost-effectiveness of three EGFR-TKIs and found 
afatinib was dominated by erlotinib, while erlotinib had an ICER estimate of $12,782 per QALY 
gained compared to gefitinib (Yang et al., 2020). Arrieta et al. found that erlotinib was 
dominated by afatinib and gefitinib, and suggested afatinib as the most cost-effective option with 
an ICER of $18,640 Mexican pesos/LY gained compared to gefitinib (Arrieta et al., 2020). 
However, both Yang et al. and Arrieta et al. used data sourced from a single institution and the 
findings may not be generalizable to broader populations (Arrieta et al., 2020; Yang et al., 2020). 
In contrast, our study directly assessed the cost-effectiveness of all three EGFR-TKIs by using 
population-based, linked administrative datasets, albeit limited to a single Canadian province, 
which captured all relevant data and complete follow-up for all patients.   
Given the fact that approximately 15% of patients with non-squamous histology harbor EGFR 
mutation, we expected to identify a larger sample for our study. However, the relatively small 
sample size may be attributed to the initial challenges of implementation of biomarker testing in 
Ontario in the early 2010s, along with its associated logistical difficulties (e.g., delayed 
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turnaround times), which led chemotherapy to be used as the first-line treatment to avoid clinical 
deterioration (Cheema et al., 2017; Ellis et al., 2013). A previous study has suggested that 
approximately 1 in 4 patients do not undergo biomarker testing (Spicer, 2015).  
A strength of adopting NBR to conduct a cost-effectiveness analysis is the capability of adjusting 
for important covariates to obtain more accurate estimates of INB and its corresponding ICERs. 
In our analysis, we found several covariates associated with NB (p<0.05), including year of 
diagnosis (λ from $0-$50,000), age group (λ from $50,000-$100,000), female sex (λ from 
$50,000-$100,000), bone metastasis (λ from $0-$50,000), and brain metastasis (λ from $0-
$100,000). Contrary to previously published studies whereby estimates of effectiveness and 
treatment-related costs were inferred from multiple sources, our study was able to establish head-
to-head comparisons of these measures, which emulates the routine clinical practice associated 
with management of NSCLC. In this sense, the findings of our study minimized some of the 
threats to external validity that arise in RCT-driven model-based analyses.  
Our study had several limitations. First, while Ontario is the most populous and ethnically 
diverse province in Canada, the generalizability of our results to other populations is unclear. 
Second, the number of patients who received erlotinib between 2017-2019 was relatively small 
compared to patients who received afatinib and gefitinib. This could be explained by the fact that 
erlotinib is only publicly funded for second- and third-line settings in Ontario, though it has an 
indication for first-line treatment, as well. Another explanation may be that prescription of 
erlotinib gradually declined in clinical practice over the years. Third, the medication claims data 
indicate that a medication was dispensed, but we cannot determine whether the medication was 
actually used. Lastly, we useda mean HUS to estimate the QALYs for all EGFR-TKIs in our 
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analysis due to lack of data on progression. However, it is worth noting that several studies have 
reported comparable estimates of mean HUS across EGFR-TKIs where differences observed in 
mean HUS were very marginal (±0.01) (Jiang et al., 2019). 
Though the NBR model can adjust for influential covariates to obtain more accurate INB 
estimates, our model could not adjust for factors that were not observed or captured in the 
databases. These factors may include treatment sequencing, growing familiarity with new agents 
among practitioners, regional/institutional preference, reimbursement, and influence of 
pharmaceutical companies, among others (Fleischman et al., 2016; Schumock et al., 2004), 
though the applicability of these factors to EGFR-TKIs is unknown. Furthermore, previous 
studies have demonstrated the importance of Eastern Cooperative Oncology Group Performance 
Status (ECOG-PS) and type of EGFR mutation status (e.g., Exon19DEL, L858R) as important 
factors in treatment selection and survival (Cha et al., 2015; Hung et al., 2018; Jackman et al., 
2006; Pirker et al., 2012) However, a lack of data on ECOG-PS and EGFR mutation status 
prohibited us from carrying out further analyses involving these factors. We assumed that 
patients who received any of the three EGFR-TKI had positive EGFR mutation, regardless of the 
type. Although highly unlikely, we cannot rule out the possibility that TKIs may have been 
prescribed to EGFR wild-type patients. Lastly, since the ODB data do not capture information on 
private insurance claims and compassionate supplies, we were not able to assess prescribing 
differences stratified by payer type.  
5.6. Conclusion 
The results of the present study demonstrated that erlotinib was dominated by afatinib and 
gefitinib, while afatinib had an ICER estimate of $34,879 per LY gained or $46,506 per QALY 
gained compared to gefitinib. From our analysis, afatinib appears to be the most cost-effective 
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treatment among the three examined, if a threshold of $50,000/QALY gained was to be chosen. 
Additional studies using population-based, longitudinal data are required to accurately assess the 




Chapter 6: Discussion 
6.1. Implications for Clinical Practice  
Emerging research on treatment sequencing for EGFR-mutant NSCLC is promising, although it 
is not entirely clear which treatment sequence provides the best outcomes for each individual 
patient. In addition to treatment effectiveness and tolerability, several other factors are 
considered for treatment selection such as patient characteristics, patient preferences, and 
anticipated quality of life. Furthermore, given that all patients will inevitably experience disease 
progression during the use of EGFR-TKIs, subsequent therapy is an important consideration 
when choosing first-line treatment.  
Osimertinib is now recommended as the preferred first-line option for EGFR mutation-positive 
NSCLC. The results of the FLAURA study demonstrated prolonged OS with the use of 
osimertinib compared to first-generation TKIs in the first-line setting: 38.6 months (95%CI: 
34.5-41.8) vs. 31.8 months (95%CI: 26.6-36.0) (Ramalingam et al., 2020). However, the 
downside of the front-line use of osimertinib is the lack of subsequent treatment options in later 
lines of therapy; however, it is worth noting that approximately 30% of patients with EGFR-
mutated NSCLC never go on to receive a second-line therapy (Ramalingam et al., 2020).  
Alternative to upfront use of osimertinib, growing body of evidence suggest sequential afatinib 
followed by osimertinib as another treatment option in the first-line setting. A post hoc analysis 
of LUX-Lung 3, 6, and 7 studies demonstrated improved OS in patients who received 
osimertinib following afatinib therapy (3-year OS: 90%) (Sequist et al., 2017). Furthermore, 
results from the global, retrospective, real-world GioTag study, which investigated the use of 
afatinib followed by osimertinib showed a favorable rate of 2-year survival (80%), a median time 
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to treatment failure of 28.1 months, and OS rate of 45.7 months with sequential use (Hochmair et 
al., 2019). However, the findings of GioTag study should be interpreted with caution as potential 
immortal time bias may have been introduced as patients who died on afatinib or were unfit or 
unwilling to receive a second-line therapy were excluded from the study. Therefore, patients 
enrolled into the GioTag study may represent a healthier population and the estimates of health 
outcomes may be overestimated. A recent retrospective study among T790M mutation-positive 
patients who acquired resistance to first-generation TKIs (i.e., erlotinib and gefitinib) and 
afatinib during any line of therapy showed higher rates of ORR and prolonged disease control 
with the use of afatinib followed by osimertinib, versus the use of first-generation TKIs followed 
by osimertinib (Tamiya et al., 2018). The favorable outcomes suggest that the benefits of afatinib 
may extend beyond the first-line treatment. The findings of Chapter 4 and Chapter 5 of this 
dissertation are consistent with previous studies where higher efficacy/effectiveness was 
observed with the use of afatinib relative to first-generation TKIs.  
Apart from EGFR-TKIs, immunotherapy and combination of EGFR-TKIs and immunotherapy 
as first-line treatment has garnered much attention lately. Pre-clinical studies have shown that 
EGF-stimulated EGFR activation leads to PD-L1 overexpression by tumor cells through the 
ERK1/2-c-jun pathway (Chen et al., 2015). This suggests that the combination of anti-PD-1/PD-
L1 and EGFR-TKIs may have synergetic effects in NSCLC therapy. Although many trials have 
attempted to investigate this combination in pre-treated NSCLC cases with promising clinical 
activity, higher incidence of AEs, with most of them being grade 3/4, impeded the progress of 
these studies and even led to termination (Ahn et al., 2017; Yang et al., 2019). To date, combined 
PD-(L)1 inhibition and chemotherapy has shown clinical benefits in patients with EGFR wild-
type NSCLC and has now become the standard of care; however, the role of PD-(L)1 inhibitors 
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in EGFR-mutant NSCLC remains incompletely defined. A phase II trial of pembrolizumab in 
PD-L1 positive EGFR-mutated NSCLC in the first-line setting showed lack of efficacy, which 
resulted in termination of enrollment (Lisberg et al., 2018). Furthermore, increased risk of 
pneumonitis and hepatitis was observed in the study when subsequent EGFR-TKIs were 
administered close to or with an ICI (Lisberg et al., 2018). Therefore, PD-(L)1 inhibitors as 
single agents or in combination with a platinum doublet should not be used in the first-line 
treatment of EGFR-mutated NSCLC, and PD-L1 expression levels should not be used to select 
first-line treatment for EGFR-mutated NSCLC.  
Available data to date suggest that the efficacy/effectiveness of second- and third-generation 
EGFR-TKIs is superior to that of first-generation agents, despite a higher incidence of grade 3/4 
AEs. Based on the findings of this dissertation and previous studies, first-line treatment with 
afatinib may represent an optimal sequencing strategy for the majority of patients with EGFR 
mutation-positive NSCLC from both clinical and cost-effectiveness perspective among the 
available first- and second-generation EGFR-TKIs. 
6.2. Implications for Healthcare System  
As described previously, each chapter of this dissertation has independently advanced decision-
making around optimal treatment sequencing and resource allocation associated with treatments 
for NSCLC. Maintaining a sustainable healthcare system requires decision-makers to not only 
consider resource allocation decisions at the introduction of novel therapies, but also to 
periodically revise allocation decisions for previously reimbursed interventions. Despite the 
comprehensive review and assessment of new health technologies, the recommendations and 
decisions for reimbursements are often accompanied with many uncertainties. A major source of 
these uncertainties is largely the estimates of input parameters used in the models due to lack of 
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data. The most common way that parameter uncertainties are introduced into a model is by using 
data from sources that represent a different patient population or country, and assumptions in the 
absence of data. Longitudinal data continuously accumulated over the years allows us to reassess 
these uncertainties and generate more accurate evidence for reimbursement decisions. This 
dissertation demonstrated that with population-based, longitudinal, person-level administrative 
data, employment of a simple regression technique allows for the generation of real-world 
evidence of effectiveness, healthcare resource utilization, and costs for previously reimbursed 
therapies. To date, the present dissertation was the first of its kind to generate real-world 
evidence on the comparative clinical and cost-effectiveness of EGFR-TKIs in Canada. The 
findings of the studies presented in this dissertation contributes to the body of knowledge on 
comparative effectiveness of EGFR-TKIs and may assist healthcare decision-makers in 
improving resource allocation decisions.  
6.3. Limitations and Future Research 
The studies presented in this thesis has several limitations that are common to studies using 
claims and medical records databases. First, claims data are primarily collected for 
reimbursement purposes rather than research purposes. On a related matter, information on 
claims are subject to errors of omission and/or commission. Without access to patients’ medical 
records for verifications, it is possible that some patients in the study sample may have been 
misclassified by their histological subtypes (SCLC versus NSCLC) or other measures of interest 
(e.g., clinical stage). Second, studies pertaining to Chapter 4 and Chapter 5 included patients 
drawn from the OCR, which comprise population only in Ontario; generalizability of results to 
the Canadian population as a whole or other countries may be limited. Third, prescription claims 
do not contain information on the indication(s) for which the medications are dispensed. 
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Moreover, pharmacy claims indicate that a medication was dispensed, but not whether or how it 
was used. Relatedly, healthcare claims will not include information on medications administered 
during hospitalizations, or of the dispensing and use of free samples. However, it is worth noting 
that the impact of this issue is likely minimal since EGFR-TKIs are dispensed mainly from 
specialty pharmacies on outpatient basis. Lastly, as with all real-world data studies, there may 
have been unmeasured confounding and missing data (e.g., EGFR mutation status, ECOG-PS), 
which may have had an impact on the estimates of study outcomes.     
Several areas for future research have been identified through the research conducted for this 
dissertation. First, while pre-clinical and clinical studies have shown promising results and 
feasibility of the use of combination regimens consisting of EGFR-TKIs and immunotherapies as 
first-line treatment for EGFR mutation-positive NSCLC, there were no clear signals that this 
may be an effective strategy. While Chapter 3 of this thesis demonstrated effectiveness 
consistent with what was observed in the trials for nivolumab, the results are not specific to 
EGFR mutation-positive NSCLC.  Further understanding of differences in the tumor 
microenvironment between EGFR mutant and EGFR wild-type NSCLC will be necessary for 
proper drug development in this patient population. A recent study by Yang et al. reports 
gefitinib plus immunotherapy (i.e., pembrolizumab) is not tolerable and this is clear (Yang et al., 
2019). However, findings supporting the notion that erlotinib plus pembrolizumab are safe are 
somewhat premature (Yang et al, 2019). Several phase I/II trials investigating the combination of 
PD-(L)1 inhibitors and EGFR-TKIs failed to show additive activity compared to EGFR-TKI 
monotherapy (Ahn et al., 2016; Creelan et al., 2019; Gettinger et al., 2018; Rudin et al., 2018; 
Yang et al., 2019). Moreover, clear safety signals emerged, which led to early discontinuation of 
enrollment and/or trials investigating the combination of ICIs and EGFR-TKIs (Ahn et al., 2016; 
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Yang et al., 2019). However, the clinical benefits of combination ICI and chemotherapy in 
EGFR-mutant NSCLC remain investigative; the IMpower150 trial demonstrated improved PFS 
and OS among patients who received carboplatin/paclitaxel in combination with atezolizumab 
and bevacizumab compared with carboplatin/paclitaxel with bevacizumab or atezolizumab 
(Socinski et al., 2018). However, the IMpower130 trial failed to show a survival benefit in the 
subset of population with EGFR/ALK alterations, despite demonstrating PFS and OS benefits in 
the wild-type population (West et al., 2019).  Larger, prospective studies should be conducted to 
verify these findings before a definitive role of ICI and chemotherapy can be pronounced for 
patients with EGFR-mutant lung cancer. Note, there are currently two large phase III trials 
ongoing: 1) KEYNOTE-789 comparing platinum-doublet chemotherapy with/without 
pembrolizumab in patients with TKI-resistant EGFR-mutant NSCLC, and 2) CheckMate 722 
comparing platinum-doublet chemotherapy with/without nivolumab in patients with metastatic 
EGFR-mutant NSCLC after disease progression on first- or second-line EGFR inhibition.  
The findings of this thesis support afatinib as the optimal first-line treatment for EGFR-mutant 
NSCLC. However, it is worth noting that osimertinib, which is now the preferred first-line 
treatment, was not considered in the studies (Chapter 4 and Chapter 5) due to lack of data. While 
several studies have demonstrated superior efficacy of front-line use of osimertinib (Cheng et al., 
2021; Ramalingam et al., 2020; Soria et al., 2018), lack of subsequent treatment options, along 
with high acquisition costs connote that osimertinib may not be the most cost-effective option in 
the first line setting (Aguiar et al., 2018; Wu et al., 2018). A head-to-head trial of afatinib versus 
osimertinib, or large, population-based, longitudinal studies of outcomes and costs associated 
with consecutive sequencing of EGFR-TKIs is needed before any conclusions can be reached. 
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Strategies for the management of NSCLC are evolving faster than ever before with new 
generations of treatments and novel therapies emerging rapidly. While new technologies improve 
health outcomes, they come with their own set of concerns, including high costs, uncertainties in 
effectiveness, and complicated treatment sequences. To inform decision-making in this area, this 
dissertation provides up-to-date evidence on the comparative- and cost-effectiveness of EGFR-
TKIs and immunotherapies.  
The goal of this dissertation was to generate high-quality evidence that would ultimately lead to 
more informed decision-making for the management of NSCLC. The evidence generated by this 
dissertation work provides insight on the treatment patterns and use of EGFR-TKIs in Ontario at 
the population-level. Furthermore, the studies in this dissertation provides important parameter 
estimates that may be used in future studies assessing the cost-effectiveness of treatments that 
can be used to revise reimbursement decisions (e.g., upon maturity of data on osimertinib or 




Chapter 7: Summary of Key Points 
7.1. What We Knew 
• While EGFR-TKIs demonstrated superior efficacy over standard chemotherapy for the 
treatment of EGFR mutation-positive NSCLC in the first line setting, the comparative 
effectiveness of first- and second-generation EGFR-TKIs in the real-world settings 
remained unclear. 
• Available EGFR-TKIs were assumed to be used interchangeably in clinical practice, 
though the degree to which patient characteristics affected prescribing decisions and 
overall survival remained largely unknown. 
• Studies published to date have shown mixed implications in comparative cost-
effectiveness of EGFR-TKIs. 
• While immunotherapies have shown superior efficacy over standard chemotherapy in the 
second line setting among EGFR wild type lung cancer patients, the effectiveness in 
clinical practice remained unknown. 
7.2. What the Dissertation Adds to the Literature 
• Identified patient demographic (e.g., age, sex, geographic residency) and clinical (e.g., 
sites of metastasis, comorbidities) factors influencing treatment selection and overall 
survival associated with first-line EGFR-TKIs. 
• Estimated comparative cost-effectiveness of afatinib, erlotinib, and gefitinib. In Ontario, 
afatinib was shown to be more cost-effective over erlotinib and gefitinib, while erlotinib 
was the least cost-effective option in the first line setting. 
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• The effectiveness of nivolumab was consistent with what was reported in the clinical 
trials, though the application to EGFR-mutant NSCLC remains unknown. 
7.3. What We Need to Do Next 
• Conduct trials and RWE studies to investigate the comparative clinical/cost-effectiveness 
between osimertinib versus afatinib for the treatment of EGFR mutation-positive NSCLC 
in the first line setting. 
• Perform similar analyses using real-world data (e.g., registries, claims data, electronic 
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Appendix A. Search Strategy 
PubMed 
(lung neoplasm[MeSH:noexp] OR Carcinoma, Non-Small-Cell Lung[MeSH] OR NSCLC*[tiab] OR lung adenocarcinom*[tiab] OR 
lung ca*[tiab]) AND (antibodies, monoclonal[MeSH: noexp] OR pembrolizumab[tiab] OR pembrolizumab[Supplementary Concept] 
OR nivolumab[tiab] OR nivolumab[MeSH] OR atezolizumab[tiab] OR atezolizumab[Supplementary Concept] OR immune 
checkpoint[tiab] OR PD-1[tiab] OR PD-L1[tiab]) AND (real world[tiab] OR real life[tiab] OR cohort studies[MeSH] OR cohort 
stud*[tiab] OR cohort analysis[tiab] OR "clinical experience"[tiab] OR "clinical practice"[tiab] OR retrospective stud*[tiab] OR 








(TS=(“lung cancer*” OR “NSCLC” OR “lung adenocarcinoma” OR “lung carcinoma” 
OR “lung neoplasm”)) AND LANGUAGE: (English) AND DOCUMENT TYPES: 
(Article) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI 
Timespan=2015-2019 
#2 
(TS=(“pembrolizumab” OR “nivolumab” OR “atezolizumab” OR “immune 
checkpoint” OR “PD-1” OR “PD-L1”)) AND LANGUAGE: (English) AND 
DOCUMENT TYPES: (Article) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI 
Timespan=2015-2019 
#3 
(TS=(“real world” OR “real life” OR “cohort” OR “retrospective” OR “prospective” 
OR “clinical practice” OR “clinical experience” OR “follow-up” OR “longitudinal”)) 





Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI 
Timespan=2015-2019 
#4 
#3 AND #2 AND #1 









#1 exp non small cell lung cancer 
#2 non small cell lung carcinoma.ab,ti. 
#3 non small cell lung cancer.ab,ti. 
#4 NSCLC.ab,ti. 
#5 lung adenocarcinoma.ab,ti. 
#6 (lung and (neoplasm$ or cancer$ or carcinom$)).ab,ti. 




#11 exp cancer immunotherapy/ 
#12 pd-1.ab,ti. 
#13 pd-l1.ab,ti. 
#14 8 or 9 or 10 or 11 or 12 or 13 





#16 real world.ab,ti. 
#17 real life.ab,ti. 
#18 exp cohort analysis/ 
#19 cohort stud*.ab,ti. 
#20 retrospective stud*.ab,ti. 
#21 prospective stud*.ab,ti. 
#22 follow up stud*.ab,ti. 
#23 longitudinal*.ab,ti. 
#24 clinical practice.ab,ti. 
#25 clinical experience.ab,ti. 
#26 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 
#27 15 and 26 
#28 27 not conference abstract.pt. 









(Out of 6) Representativeness of 



















Areses Manrique et al. ★ ★ ★ ★   4 
Bagley et al.  ★ ★  ★  ★     4 
Brustugun, Sprauten & Helland  ★ ★ ★ ★ ★  5 
Costantini et al.  ★ ★ ★ ★ ★ ★ 6 
Crino et al.  ★ ★ ★ ★ ★ ★ 6 
Diem et al.  ★ ★ ★ ★   4 
Dudnik et al.  ★ ★ ★ ★ ★ ★ 6 
Dumenil et al.  ★ ★ ★ ★   4 
Facchinetti et al.  ★ ★ ★ ★ ★  5 
Fiorica et al.  ★ ★ ★ ★ ★ ★ 6 
Fujimoto et al.  ★ ★ ★ ★   4 
Fukui et al.  ★ ★ ★ ★ ★  5 
Garde-Noguera et al.  ★ ★ ★ ★   4 
Garassino et al.  ★ ★ ★ ★ ★  5 
Grossi et al.  ★ ★ ★ ★ ★  5 
Haratani et al.  ★ ★ ★ ★ ★  5 
Juergens et al.  ★ ★ ★ ★ ★  5 
Kataoka et al.  ★ ★ ★ ★   4 
Kiriu et al.  ★ ★ ★ ★   4 
Kobayashi et al.  ★ ★ ★ ★   4 
Lesueur et al. ★ ★ ★ ★ ★  5 
Merino Almazan et al.  ★ ★ ★ ★   4 
Montana et al.  ★ ★ ★ ★   4 
Sabatier et al.  ★ ★ ★ ★ ★ ★ 6 
Sato et al.  ★ ★ ★ ★   4 
Schmid et al.  ★ ★ ★ ★ ★  5 







(Out of 6) Representativeness of 



















Sekine et al.  ★ ★ ★ ★   4 
Shamai & Merimsky  ★ ★ ★ ★ ★  5 
Shiroyama et al.  ★ ★ ★ ★ ★  5 
Takeda et al.  ★ ★ ★ ★   4 
Tiu et al.  ★ ★ ★ ★   4 
Tournoy et al.  ★ ★ ★ ★ ★  5 
Cohort 
Author  
Selection Comparability Outcome 
Score 
(Out of 9) 
Representativeness 
of the Exposed 
Cohort 

























Calpe-Armero et al.  ★ ★ ★ ★ ★ ★   6 
Ksienski et al.  ★ ★ ★ ★ ★ ★ ★  7 




Appendix C. Summary of studies investigating the association between independent factors and 
overall survival associated with nivolumab 
Author Sample Size Intervention 






Areses Manrique et al. 188 Nivolumab 






Bagley et al. 175 Nivolumab 
3mg/kg per 2 weeks 
NR Age (<75 vs. ≥75): 
1.1 (0.7-1.8)  
NR 
Diem et al. 52 Nivolumab 
3mg/kg per 2 weeks 
NR Age (per year): 
1.01 (0.96-1.06) 
0.841 
Dudnik et al. 260 Nivolumab 





1.02* (0.99-1.04) 0.06 
Dumenil et al. 67 Nivolumab 
3mg/kg per 2 weeks 
NR Age (<70 vs. ≥70): 
0.22 (0.81-2.59) 
0.215 
Facchinetti et al. 54 Nivolumab 






Fukui et al. 52 Nivolumab 
3mg/kg per 2 weeks 
NR Age (<75 vs. ≥75): 
0.34 (0.08-1.45) 
0.15 
Garde-Noguera et al. 175 Nivolumab 






Grossi et al. 371 Nivolumab 







Age (≥75 vs. 65-<75): 
1.15 (0.82-1.61)  
0.42 
Juergens et al. 472 Nivolumab 







Age (65-75 vs. <65): 
0.88 (0.68-1.15) 







Author Sample Size Intervention 





Ksienski et al. 271 Nivolumab 
3mg/kg per 2 weeks 
Pembrolizumab 
2mg/kg per 3 weeks 
NR Nivolumab 
Age (≥64 vs. <64): 
0.83* (0.56-1.23) 
0.352 
Merino Almazan et al. 221 Nivolumab 





0.95 (0.61-1.49) 0.821 
Montana et al. 98 Nivolumab 







Areses Manrique et al. 188 Nivolumab 






Bagley et al. 175 Nivolumab 
3mg/kg per 2 weeks 
NR Male vs. Female: 
1.39 (0.9-2.1) 
NR 
Diem et al. 52 Nivolumab 
3mg/kg per 2 weeks 
NR Male vs. Female: 
0.76* (0.25-2.32) 
0.629 
Dudnik et al. 260 Nivolumab 





1.16* (0.79-1.69) 0.43 
Dumenil et al. 67 Nivolumab 
3mg/kg per 2 weeks 
NR Male vs. Female: 
1.25 (0.68-2.31) 
0.475 
Facchinetti et al. 54 Nivolumab 






Fukui et al. 52 Nivolumab 
3mg/kg per 2 weeks 
NR Male vs. Female: 
1.37 (0.54-3.43) 
0.51 
Garde-Noguera et al. 175 Nivolumab 






Grossi et al. 371 Nivolumab 
3mg/kg per 2 weeks 
NR Male vs. Female: 
1.67 (1.05-2.64) 
0.03 
Ksienski et al. 271 Nivolumab: NR Nivolumab: 0.224 
 
139 
Author Sample Size Intervention 





3mg/kg per 2 weeks 
Pembrolizumab: 
2mg/kg per 3 weeks 
Male vs. Female: 
1.27* (0.86-1.87) 
Lesueur et al. 104 Nivolumab 
3mg/kg per 2 weeks 
NR 0.85 (0.55-0.62) 0.845 
Merino Almazan et al. 221 Nivolumab 





0.76 (0.44-1.32) 0.326 
Montana et al. 98 Nivolumab 






Schouten et al. 248 Nivolumab 




13.1 (Not Reached) 
0.968* (0.62-1.51) 0.886 
ECOG-PS 
Areses Manrique et al. 188 Nivolumab 








Bagley et al. 175 Nivolumab 
3mg/kg per 2 weeks 
NR ECOG (≥2 vs. <2): 
2.49* (1.6-3.9) 
NR 
Diem et al. 52 Nivolumab 
3mg/kg per 2 weeks 




Dudnik et al. 260 Nivolumab 
3mg/kg per 2 weeks 
ECOG 0-1: 
9.5 (6.7-Not Reached) 
ECOG ≥2: 
3.5 (2.6-4.5) 
HR: 1.86* (1.31-2.65) 0.0006 
Dumenil et al. 67 Nivolumab 
3mg/kg per 2 weeks 
NR ECOG (2 at start of 
nivolumab therapy):  
2.20* (0.89-5.42) 
0.086 
Facchinetti et al. 54 Nivolumab 




1.8 (0-3.8)  
3.86* (1.66-9.02) 0.002 
Fiorica et al. 35 Nivolumab NR ECOG (2 vs <2): 0.001 
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Author Sample Size Intervention 





3mg/kg per 2 weeks 8.8 (3.08-25.18) 
Fukui et al. 52 Nivolumab 
3mg/kg per 2 weeks 
NR ECOG (0 vs. 1-3): 
1.64* (0.43-6.25) 
0.47 
Garde-Noguera et al. 175 Nivolumab 
3mg/kg per 2 weeks 
NR ECOG (0-1 vs. 2): 
0.62* (0.36-1.04) 
0.073 
Grossi et al. 371 Nivolumab 
3mg/kg per 2 weeks 
NR ECOG (2 vs. 0-1): 
1.69 (0.94-3.05) 
0.08 
Juergens et al. 472 Nivolumab 





1.64* (1.11-2.43) 0.01 
Ksienski et al. 271 Nivolumab 
3mg/kg per 2 weeks 
Pembrolizumab 
2mg/kg per 3 weeks 
NR Nivolumab 
ECOG (≥2 vs. 0/1): 
2.76* (1.86-4.10) 
<0.001 
Lesueur et al. 104 Nivolumab 
3mg/kg per 2 weeks 
NR ECOG PS >1: 
1.81* (0.96-3.42) 
0.07 
Merino Almazan et al. 221 Nivolumab 





0.29* (0.18-0.467) <.0001 
Montana et al. 98 Nivolumab 





ECOG ≥2:  
3.09 (2.37-6.21) 
NR 0.00421 
Schouten et al. 248 Nivolumab 





2.4* (1.34-4.31) 0.003 








Areses Manrique et al. 188 Nivolumab 






Author Sample Size Intervention 







Bagley et al. 175 Nivolumab 
3mg/kg per 2 weeks 




Costantini et al. 303 Nivolumab 





1.47 (0.96-2.27) 0.079 
Diem et al. 52 Nivolumab 
3mg/kg per 2 weeks 




Dudnik et al. 260 Nivolumab 





1.12* (0.73-1.70) 0.61 
Dumenil et al. 67 Nivolumab 
3mg/kg per 2 weeks 




Facchinetti et al. 54 Nivolumab 
3mg/kg per 2 weeks 
Squamous:  
5.5 (NR) 
Adenocarcinoma: 6.6 (4.7-8.5) 
NR 0.724 
Fiorica et al. 35 Nivolumab 
3mg/kg per 2 weeks 




Fukui et al. 52 Nivolumab 
3mg/kg per 2 weeks 




Garde-Noguera et al. 175 Nivolumab 






Juergens et al. 472 Nivolumab 





0.95* (0.72-1.26) 0.71 
Ksienski et al. 271 Nivolumab 
3mg/kg per 2 weeks 
Pembrolizumab 
2mg/kg per 3 weeks 
Nivolumab:  
Squamous: 
12.9 (5.6-Not Reached) 
Non-squamous: 
8.5 (7.1-10.7) 






Author Sample Size Intervention 





Lesueur et al. 104 Nivolumab 




Merino Almazan et al. 221 Nivolumab 





0.59* (0.38-0.91) 0.019 
Schouten et al. 248 Nivolumab 





0.47* (0.25-0.91) 0.026 
CI – Confidence Interval; OS - Overall Survival; HR – Hazard Ratio; ECOG PS – Eastern Cooperative Oncology Group Performance Status; NR – Not 
Reported; *- Adjusted HR  
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Appendix D. Summary of studies investigating the association between independent factors and 
progression-free survival associated with nivolumab. 
Author Sample Size Intervention 






Bagley et al. 175 Nivolumab 
3mg/kg per 2 weeks 
NR Age (<75): 
1.29 (0.9-1.9) 
NR 
Diem et al. 52 Nivolumab 
3mg/kg per 2 weeks 
NR Age (per year): 
0.96 (0.92-1.01) 
0.091 
Dumenil et al. 67 Nivolumab 
3mg/kg per 2 weeks 




Garde-Noguera et al. 175 Nivolumab 
3mg/kg per 2 weeks 
Age <70: 
2.4 (NR) 
Age ≥70:  
3.7 (NR) 
NR 0.756 
Grossi et al. 371 Nivolumab 




4.5 (3.5-5.5)  
Age ≥75: 
3.2 (1.1-5.3)  
NR NR 
Merino Almazan et al. 221 Nivolumab 





0.92 (0.62-1.36) 0.662 
Montana et al. 98 Nivolumab 








Author Sample Size Intervention 





Shiroyama et al. 201 Nivolumab 
3mg/kg per 2 weeks 




Bagley et al. 175 Nivolumab 
3mg/kg per 2 weeks 
NR Sex (Male): 
1.41 (1.02-1.90) 
NR 
Diem et al. 52 Nivolumab 
3mg/kg per 2 weeks 
NR Sex (Male): 
0.94* (0.42-2.11( 
0.880 
Dumenil et al. 67 Nivolumab 
3mg/kg per 2 weeks 
NR Sex (Male): 
0.85 (0.45-1.61) 
0.609 
Garde-Noguera et al. 175 Nivolumab 






Lesueur et al. 104 Nivolumab 
3mg/kg per 2 weeks 
NR Sex (Not Specified): 
0.91 (0.59-1.41) 
0.685 
Merino Almazan et al. 221 Nivolumab 





0.72 (0.44-1.18) 0.191 
Montana et al. 98 Nivolumab 






Schouten et al. 248 Nivolumab 





0.965* (0.67-1.38) 0.845 
Shiroyama et al. 201 Nivolumab 
3mg/kg per 2 weeks 






Author Sample Size Intervention 





Bagley et al. 175 Nivolumab 
3mg/kg per 2 weeks 
NR ECOG (≥2 vs. 0/1): 
1.89* (1.3-2.8) 
NR 
Diem et al. 52 Nivolumab 
3mg/kg per 2 weeks 




Dumenil et al. 67 Nivolumab 
3mg/kg per 2 weeks 
ECOG 0-1:  
6.6 (IQR: 1.9-13.7) 
ECOG 2: 
1.1 (IQR: 0.8-3.7) 
5.17* (1.99-13.43) 0.001 
Kataoka et al. 189 Nivolumab 
3mg/kg per 2 weeks 
NR ECOG (≥2 vs. 0/1): 
1.94* (1.29-2.92) 
0.003 
Lesueur et al. 104 Nivolumab 
3mg/kg per 2 weeks 
NR ECOG (>1): 
1.81* (0.96-3.42) 
0.07 
Merino Almazan et al. 221 Nivolumab 





3.94 (2.53-6.11) <.0001 
Montana et al. 98 Nivolumab 








Schouten et al. 248 Nivolumab 





1.25* (0.75-2.10) 0.396 
Shiroyama et al. 201 Nivolumab 
3mg/kg per 2 weeks 






Author Sample Size Intervention 





Bagley et al. 175 Nivolumab 




Costantini et al. 303 Nivolumab 






Dumenil et al. 67 Nivolumab 
3mg/kg per 2 weeks 




Garde-Noguera et al. 175 Nivolumab 






Lesueur et al. 104 Nivolumab 




Kataoka et al. 189 Nivolumab 




Merino Almazan et al. 221 Nivolumab 





0.79 (0.55-1.14) 0.212 
Schouten et al. 248 Nivolumab 





0.81* (0.50-1.31) 0.388 
Shiroyama et al. 201 Nivolumab 




CI – Confidence Interval; OS - Overall Survival; HR – Hazard Ratio; ECOG PS – Eastern Cooperative Oncology Group Performance 
Status; NR – Not Reported; *- Adjusted HR
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Appendix F. GRADE table for overall survival and progression-free survival associated with 
nivolumab. 



























3594  -  
9.6 months 
(8.4 – 10.9) 
⨁◯◯◯ 
















1140  -  
2.6 months 
(1.6 – 3.6) 
⨁◯◯◯ 
VERY LOW  
CI: Confidence Interval 
a. Some variance of point estimates across studies 
b. Considerable statistical heterogeneity 
c. Funnel plot suggests presence of publication bias 









Net Benefits λ = 0 Net Benefits λ = 20000 Net Benefits λ = 50000 Net Benefits λ = 100000 







































































































































































































0.0011 0.4274 0.0009 0.3826 0.0038 0.2339 0.0039 0.0572 




Appendix H. Estimates of Incremental Net Benefit and Probability of Cost-Effectiveness of 
Afatinib, Erlotinib, and Gefitinib - LY 
 Threshold 

















$0 -9745 (6350) 0.126 0.022 1549 (10948) 0.888 0.703 13610 (9458) 0.151 0.919 
$10,000 -6951 (5994) 0.247 0.040 8566 (10140) 0.399 0.892 16144 (8955) 0.072 0.984 
$20,000 -4157 (5744) 0.470 0.095 15583 (9487) 0.102 0.987 18678 (8579) 0.030 0.998 
$30,000 -1363 (5616) 0.808 0.209 22600 (9025) 0.013 1.000 21213 (8345) 0.011 1.000 
$40,000 1431 (5617( 0.799 0.402 29616 (8783) 0.001 1.000 23747 (8266) 0.004 1.000 
$50,000 4225 (5747) 0.463 0.602 36633 (8780) <.001 1.000 26281 (8346) 0.002 1.000 
$60,000 7019 (5999) 0.243 0.752 43650 (9015) <.001 1.000 28816 (8581) 0.001 1.000 
$70,000 9813 (6357) 0.123 0.865 50667 (9471) <.001 1.000 31350 (8959) 0.001 1.000 
$80,000 12607 (6804) 0.065 0.927 57684 (10118) <.001 1.000 33884 (9462) <.001 1.000 
$90,000 15401 (7326) 0.036 0.958 64701 (10922) <.001 1.000 36419 (10073) <.001 1.000 
$100,000 18195 (7906) 0.022 0.974 71718 (11851) <.001 1.000 38953 (10772) <.001 1.000 
$150,000 32165 (11346) 0.005 0.992 106803 (17605) <.001 1.000 51624 (15118) <.001 1.000 
$200,000 46135 (15222) 0.003 0.995 141888 (24199) <.001 1.000 64296 (20181) 0.002 1.000 









Appendix I. Incremental Net Benefit by Willingness-To-Pay for 
Afatinib versus Gefitinib - LY 
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Appendix J. Cost Effectiveness Acceptability Curve for Afatinib 
versus Gefitinib - LY 
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